<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd"><PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36443608</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2584</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International urology and nephrology</Title><ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation></Journal><ArticleTitle>The danger of hyperoxia on the rat kidneys: is tadalafil a real shield?</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>247</EndPage><MedlinePgn>241-247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-022-03416-w</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Continuous oxygen therapy to compensate for decreased oxygen saturation in the blood is a life-saving treatment used in case lung involvement. Excess oxygen delivery was reported to be a common situation, in which about 50% of the patients showed hyperoxemia and 4% in severe hyperoxemia. In this work, we investigated the effects of hyperoxia on the rat kidneys and whether tadalafil has an effect to reduce this damage.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Three groups of 8 male rats each weighing 300-350&#xa0;g were formed. The groups were divided into the control group, hyperoxia group, and hyperoxia and tadalafil administered group for 10 days. At the end of the 10th day, blood and kidney samples were taken for biochemical analysis (SOD and NO levels) and histopathological examination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While our findings showed that SOD levels were significantly different among the control and experimental groups and within the experimental groups, no statistical difference was found in terms of NO levels among the groups (Table 1). While the glomerular and tubular injury was higher in the Hyperoxia group and the Hyperoxia&#x2009;+&#x2009;Tadalafil group than in the control group (p&#x2009;&lt;&#x2009;0.001), as a result of the rate of severe glomerular and tubular injury in the hyperoxia group, was 62.5% and 43.8% and in the group given tadalafil was 43.8% and 31.3%, respectively (Table 2).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Exposure to hyperoxia condition causes renal glomerular and tubular damage, and tadalafil does not show a protective effect on this damage according to this study's dose and exposure time.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kilicarslan</LastName><ForeName>Nermin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Anesthesia Department, Bursa Y&#xfc;ksek &#x130;htisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demir</LastName><ForeName>Aslan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3089-7870</Identifier><AffiliationInfo><Affiliation>Urology Department, Medical Faculty, Dragos Hospital, Bezmialam Foundation University, Dragos Hastanesi, Sahil Yolu Sok. No: 16 Maltepe, 34844, Istanbul, Turkey. benaslandemir@yahoo.com.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeni</LastName><ForeName>Sezgin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Urology Department, Medical Faculty, Bursa Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicek</LastName><ForeName>Mehmet Cagatay</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Urology Department, Medical Faculty, Bursa Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saricetin</LastName><ForeName>Aysun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology Department, Veterinary Faculty, Bursa Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dirican</LastName><ForeName>Melahat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biochemistry Department, Medical Faculty, Bursa Uludag University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Urol Nephrol</MedlineTA><NlmUniqueID>0262521</NlmUniqueID><ISSNLinking>0301-1623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018496" MajorTopicYN="Y">Hyperoxia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hyperoxia</Keyword><Keyword MajorTopicYN="N">Nitric oxide</Keyword><Keyword MajorTopicYN="N">Rat kidneys</Keyword><Keyword MajorTopicYN="N">Superoxide dismutase</Keyword><Keyword MajorTopicYN="N">Tadalafil</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>28</Day><Hour>23</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36443608</ArticleId><ArticleId IdType="pmc">PMC9707269</ArticleId><ArticleId IdType="doi">10.1007/s11255-022-03416-w</ArticleId><ArticleId IdType="pii">10.1007/s11255-022-03416-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yeni S, Demir A, Kilicarslan N, Cicek MC, Saricetin A, Dirican M, et al. Tadalafil against hyperoxia-induced oxidative stress; an experimental study. Andrologia. 2022;54:e14494. doi: 10.1111/and.14494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/and.14494</ArticleId><ArticleId IdType="pubmed">35676072</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang JS, Chou HC, Yeh TF, Chen CM. Neonatal hyperoxia exposure induces kidney fibrosis in rats. Pediatr and Neonatal. 2015;56(4):235&#x2013;241. doi: 10.1016/j.pedneo.2014.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pedneo.2014.11.003</ArticleId><ArticleId IdType="pubmed">25572324</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteban A, Anzuento A, Alia I, Gordo F, Apezteguia C, Palizas F, Cide D, et al. How is mechanical ventilation employed in the intensive care unit? an international review. Am J Respir Crit Care Med. 2000;61(5):1450&#x2013;1458. doi: 10.1164/ajrccm.161.5.9902018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.161.5.9902018</ArticleId><ArticleId IdType="pubmed">10806138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni YN, Wang YM, Liang BM, Liang ZA. The effect of hyperoxia on mortality in critically ill patients: a systematic review and meta analysis. BMC Pulm Med. 2019;19:53. doi: 10.1186/s12890-019-0810-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-019-0810-1</ArticleId><ArticleId IdType="pmc">PMC6390560</ArticleId><ArticleId IdType="pubmed">30808337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen JK, Bonnesen B, Hansen EF, Jensen JS, Lapperre TS, Weinreich UM, Hilberg O. Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. Eur Clin Respir J. 2020;7:1761677. doi: 10.1080/20018525.2020.1761677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20018525.2020.1761677</ArticleId><ArticleId IdType="pmc">PMC7655082</ArticleId><ArticleId IdType="pubmed">33224450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari V, Maulik N, Kresch M. Hyperoxia causes an increase in antioxidant enzyme activity in adult and fetal rat type II pneumocytes. Lung. 2000;178(1):53&#x2013;60. doi: 10.1007/s004080000006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004080000006</ArticleId><ArticleId IdType="pubmed">10723720</ArticleId></ArticleIdList></Reference><Reference><Citation>Barazzone C, White CW. Mechanisms of cell injury and death in hyperoxia: role of cytokines and Bcl-2 familiy proteins. Am J Respir Cell Mol Biol. 2000;22(5):517&#x2013;519. doi: 10.1165/ajrcmb.22.5.f180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/ajrcmb.22.5.f180</ArticleId><ArticleId IdType="pubmed">10783120</ArticleId></ArticleIdList></Reference><Reference><Citation>Verratti V, Di Giulio C, Berardinelli F, Tiboni GM, Pellicciotta M, Brunetti L, Ferrante C, et al. Pampiniform plexus and oxidative stress during chronic hypoxia and hyperoxia. Int J Immunopathol Pharmacol. 2008;21(2):353&#x2013;357. doi: 10.1177/039463200802100212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463200802100212</ArticleId><ArticleId IdType="pubmed">18547479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa T, Anis TH, Ghazi S, El-Nashar AR, Imam H, Osman IA. Reactive oxygen species and antioxidants relationship in the internal spermatic vein blood of infertile men with varicocele. Asian J Androl. 2006;8(4):451&#x2013;455. doi: 10.1111/j.1745-7262.2006.00172.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7262.2006.00172.x</ArticleId><ArticleId IdType="pubmed">16763721</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PHJ, Bosman RJ, et al. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Crit Care. 2008;12(6):R156. doi: 10.1186/cc7150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7150</ArticleId><ArticleId IdType="pmc">PMC2646321</ArticleId><ArticleId IdType="pubmed">19077208</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman BA, Crapo JD. Free radicals and tissue injury. Lab Invest. 1982;47(5):412&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">6290784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118&#x2013;126. doi: 10.4103/0973-7847.70902.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0973-7847.70902</ArticleId><ArticleId IdType="pmc">PMC3249911</ArticleId><ArticleId IdType="pubmed">22228951</ArticleId></ArticleIdList></Reference><Reference><Citation>Dr&#xf6;ge W. Free radicals in the physiological control of cell function. Physiol Rev. 2022;82(1):47&#x2013;95. doi: 10.1152/physrev.00018.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00018.2001</ArticleId><ArticleId IdType="pubmed">11773609</ArticleId></ArticleIdList></Reference><Reference><Citation>Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological funcitons and human disease. Int J Biochem Cell Biol. 2007;39(1):44&#x2013;84. doi: 10.1016/j.biocel.2006.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.07.001</ArticleId><ArticleId IdType="pubmed">16978905</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikan DC, Bakan V, Kurutas EB, Sayar H, Coskum A. Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary. J Pediatr Surg. 2010;45(11):2203&#x2013;2209. doi: 10.1016/j.jpedsurg.2010.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpedsurg.2010.07.011</ArticleId><ArticleId IdType="pubmed">21034945</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the Rabbit. Prostate. 2013;73:428&#x2013;441. doi: 10.1002/pros.22584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.22584</ArticleId><ArticleId IdType="pubmed">22996758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto M, Zhang X, Ueda N, Tsunemori H, Taoka R, Hayashida Y, Hirama H, et al. A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. BMC Urol. 2019;19:99. doi: 10.1186/s12894-019-0525-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12894-019-0525-x</ArticleId><ArticleId IdType="pmc">PMC6806527</ArticleId><ArticleId IdType="pubmed">31646996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozmerdiven G, Vuruskan BA, Kaygisiz O, Vuruskan H. Protective effects of diltiazem and tadalafil on shock wave-induced kidney injury in rats. Bratisl Lek Listy. 2017;118(4):228&#x2013;232. doi: 10.4149/BLL_2017_045.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/BLL_2017_045</ArticleId><ArticleId IdType="pubmed">28471234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale KE, Gavin C, O&#x2019;Driscoll BR. Audit of oxygen use in emergency ambulances and in a hospital emergency department. Emerg Med J. 2008;25(11):773&#x2013;776. doi: 10.1136/emj.2008.059287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emj.2008.059287</ArticleId><ArticleId IdType="pubmed">18955625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans. 2007;35(5):1147&#x2013;1150. doi: 10.1042/BST0351147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0351147</ArticleId><ArticleId IdType="pubmed">17956298</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiani E, Donati A, Girardis M. Oxygen in the critically ill: friend or foe? Curr Opin Anaesthesiol. 2018;31(2):129&#x2013;135. doi: 10.1097/ACO.0000000000000559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0000000000000559</ArticleId><ArticleId IdType="pubmed">29334496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Alarcona C, Denicola A. Evaluating the antioxidant capacity of natural products: a review on chemical and cellular-based assays. Anal Chim Acta. 2013;763:1&#x2013;10. doi: 10.1016/j.aca.2012.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aca.2012.11.051</ArticleId><ArticleId IdType="pubmed">23340280</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Touyz RM. Reactive oxygen species and vascular remodeling in hypertension: still alive. Can J Cardiol. 2006;22(11):947&#x2013;951. doi: 10.1016/S0828-282X(06)70314-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0828-282X(06)70314-2</ArticleId><ArticleId IdType="pmc">PMC2570242</ArticleId><ArticleId IdType="pubmed">16971980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelissen H, de Grooth HJ, Smulders Y, Wils EJ, de Rujter W, Vink R, Smit B, et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. JAMA. 2021;326(10):940&#x2013;948. doi: 10.1001/jama.2021.13011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.13011</ArticleId><ArticleId IdType="pmc">PMC8408761</ArticleId><ArticleId IdType="pubmed">34463696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai SY, Pei J, Yan B, Liu ZY, Chen Y, Sima CY, Su CJ, et al. Effects of normobaric hyperoxia intervention on renal ischemia-reperfusion injury in rats. Zhonghua Yi Xue Za Zhi. 2021;101(14):1036&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">33845544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CM, Chou HC. Maternal inflammation exacerbates neonatal hyperoxia-induced kidney injury in rat offspring. Pediatr Res. 2019;86(2):174&#x2013;180. doi: 10.1038/s41390-019-0413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-019-0413-9</ArticleId><ArticleId IdType="pubmed">31086293</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Zhang X, Gao L, Liu C, You K. (2020) Neonatal hyperoxia downregulates claudin-4, occludin, and ZO-1 expression in rat kidney accompanied by impaired proximal tubular development. Oxid Med Cell Longev, p 2641461. 10.1155/2020/2641461</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725566</ArticleId><ArticleId IdType="pubmed">33343804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MF, Venkatarayappa SKB, Benny M, Rojas C, Yousefi K, Shehadeh KA, Kulandavelu S, et al. Effects of Klotho supplementation on hyperoxia-induced renal injury in a rodent model of postnatal nephrogenesis. Pediatr Res. 2020;88(4):565&#x2013;570. doi: 10.1038/s41390-020-0803-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-020-0803-z</ArticleId><ArticleId IdType="pmc">PMC8226112</ArticleId><ArticleId IdType="pubmed">32059229</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36249940</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1319-0164</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society</Title><ISOAbbreviation>Saudi Pharm J</ISOAbbreviation></Journal><ArticleTitle>Pharmaceutical equivalency of locally and regionally manufactured generic pharmaceutical products in UAE.</ArticleTitle><Pagination><StartPage>1243</StartPage><EndPage>1251</EndPage><MedlinePgn>1243-1251</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsps.2022.06.027</ELocationID><Abstract><AbstractText>Generic drugs or generic medicines are pharmaceutical products manufactured to be equivalent to the brand/innovator drug products. They represent the majority of worldwide prescribed medicines; therefore, their quality is critical to maximize patients' therapeutic outcomes. This study aimed to evaluate the pharmaceutical equivalency of locally and regionally manufactured generic pharmaceutical products being sold in the United Arab Emirates (UAE) market to enhance public confidence, promote their utilization, and reduce treatment costs. Three drugs (tadalafil, rosuvastatin, and acetaminophen) from three different pharmacological classes were selected from the UAE market as representatives for generic drugs. At least two generic products for each locally (L) and regionally (R) manufactured generic were evaluated according to the USP criteria in comparison to the brand (B) comparator product. All comparative tests were performed before storage and 3 and 6&#xa0;months after storage during the accelerated stability study performed under the conditions for climatic zone IV (40&#xa0;&#xb0;C&#xa0;&#xb1;&#xa0;2&#xa0;&#xb0;C /75% RH&#xa0;&#xb1;&#xa0;5% RH). Although results were statistically different from the comparators using ANOVA and Tukey's Kremer post hoc tests, all tests were within the USP acceptance limits, except one, for friability, disintegration, content uniformity, and dissolution. Significant changes were observed following their storage over 6&#xa0;months during accelerated stability studies, however, without failing the USP limits. Only one locally manufactured acetaminophen generic failed the USP dissolution tests before and after its storage and failed the disintegration test following its storage under accelerated conditions for zone IV. In conclusion, the majority of the locally and regionally manufactured generic products being sold in the UAE market were of good quality and performed similarly to their comparators. However, a continuous independent quality evaluation for the marketed generic drugs is essential to enhance public confidence.</AbstractText><CopyrightInformation>&#xa9; 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al Ali</LastName><ForeName>Lamia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagal</LastName><ForeName>Jayalakshmi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Jobi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Iman Saad</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawas-Qalaji</LastName><ForeName>Mutasem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33326, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Saudi Arabia</Country><MedlineTA>Saudi Pharm J</MedlineTA><NlmUniqueID>9705695</NlmUniqueID><ISSNLinking>1319-0164</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acetaminophen</Keyword><Keyword MajorTopicYN="N">Generics</Keyword><Keyword MajorTopicYN="N">Pharmaceutical equivalency</Keyword><Keyword MajorTopicYN="N">Rosuvastatin</Keyword><Keyword MajorTopicYN="N">Tadalafil</Keyword><Keyword MajorTopicYN="N">United Arab Emirates</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36249940</ArticleId><ArticleId IdType="pmc">PMC9563041</ArticleId><ArticleId IdType="doi">10.1016/j.jsps.2022.06.027</ArticleId><ArticleId IdType="pii">S1319-0164(22)00184-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdul Rasool B.K., Shamsueldin E., Sadik R., Khan S.A. Physical Characterization and In Vitro Evaluation of Some Generic Medications Available in Pharma Market of United Arab Emirates (UAE) Lat. Am. J. Pharm. 2011;30(9):1767&#x2013;1774.</Citation></Reference><Reference><Citation>ADQ FWD, 2022. Redefining Regional Pharma. Retrieved 5/10/2022 https://assets.website-files.com/61820dbf93b6572c197e5eb3/6215c6ba082289c7ef740ef3_Redefining%20Regional%20Pharma%20(Desktop).pdf.</Citation></Reference><Reference><Citation>Ahmad I., Shaikh R.H. Effect of temperature and humidity on hardness and friability of packaged paracetamol tablet formulations. Pak. J. Pharm. Sci. 1994;7(2):69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad I., Shaikh R.H. Effect of moisture on the stability of packaged paracetamol tablet formulations. Pak. J. Pharm. Sci. 2003;16(2):13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414572</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbenga B.L., Taiwo Y. Studies of the effect of storage conditions on some pharmaceutical parameters of powders and tablets. Dhaka Univ. J. Pharmaceut. Sci. 2015;14(2):147&#x2013;151.</Citation></Reference><Reference><Citation>Hanafy A.F. In-vitro bioequivalence, physicochemical and economic benefits study for marketed innovator and generic ciprofloxacin hydrochloride tablets in Saudi Arabia. J. Appl. Pharmaceut. Sci. 2016;6(9):063&#x2013;068.</Citation></Reference><Reference><Citation>Hosny E.A. Study of accelerated storage conditions affecting physical characteristics, in-vitro dissolution and stability of bioadhesive containing tablets. Boll. Chim. Farm. 1999;138(6):243&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464972</ArticleId></ArticleIdList></Reference><Reference><Citation>ICH Expert Working Group, 2003. Stability Testing of New Drug Substances and Products Q1A(R2). Retrieved 5/10/2022, from ICH Webpage https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.</Citation></Reference><Reference><Citation>Masson, A., Steiner, R.L., 1985. Generic substitution and prescription drug prices: economic effects of state drug product selection laws. Washington, D.C.: Bureau of Economics, Federal Trade Commission.</Citation></Reference><Reference><Citation>Mochizuki K., Takayama K. Prediction of color changes in acetaminophen solution using the time-temperature superposition principle. Drug Dev. Ind. Pharm. 2016;42(7):1050&#x2013;1057. doi: 10.3109/03639045.2015.1107091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03639045.2015.1107091</ArticleId><ArticleId IdType="pubmed">26559666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullaicharam A.R., Ahmed J.-A.-H.-J., Halligudi N. Evaluation of pharmaceutical equivalents of different brands of ranitidine tablets from multinational brands in Oman. Int. J. Nutrition, Pharmacol., Neurol. Dis. 2012;2(1)</Citation></Reference><Reference><Citation>Nagraj, A., 2022. UAE pharmaceutical market to be valued at $4.7bn by 2025 as it boosts local manufacturing. Retrieved 5/19/2022, from The National News https://www.thenationalnews.com/business/2022/02/23/uae-pharma-market-to-be-valued-at-47bn-by-2025-as-it-boosts-local-manufacturing/.</Citation></Reference><Reference><Citation>Otsuka M., Akizuki Y., Otsuka K., Yanagisawa S., Kamae I., Jorgenson J.A. A comparison of the technical quality of American and Japanese ranitidine tablets. Dissolution Technol. 2008;14(3):22&#x2013;28.</Citation></Reference><Reference><Citation>U.S. FDA, 2003. Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products. FDA Website Retrieved 9/5/2022, from U.S. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products.</Citation></Reference><Reference><Citation>U.S. FDA, 2018. Generic Drug Facts. FDA Website Retrieved 6/1/2022, from U.S. FDA https://www.fda.gov/drugs/generic-drugs/generic-drug-facts.</Citation></Reference><Reference><Citation>U.S. FDA, 2019a. Generic Competition and Drug Prices. FDA Website Retrieved 5/9/2022, from U.S. FDA https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices.</Citation></Reference><Reference><Citation>U.S. FDA, 2019b. Generic Drugs. FDA Website Retrieved 5/9/2022, from U.S. FDA https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs.</Citation></Reference><Reference><Citation>U.S. FDA, 2020. Preface to the Orange Book. FDA Website Retrieved 2/13/2022 https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface.</Citation></Reference><Reference><Citation>U.S. FDA, 2021. Generic Drugs: Questions &amp; Answers. FDA Website Retrieved 5/9/2022, from U.S. FDA https://www.fda.gov/drugs/questions-answers/generic-drugs-questions-answers#:~:text=A%20generic%20drug%20is%20a,performance%20characteristics%2C%20and%20intended%20use.</Citation></Reference><Reference><Citation>USP/NF, 2020a. General chapters: &#x2329;701&#x232a; Disintegration. In: United States Pharmacopea (43/38 ed., Vol. 44(2), pp. 6940&#x2013;6943). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020b. General chapters: &#x2329;711&#x232a; Dissolution. In: United States Pharmacopea (43/38 ed., Vol. 40(6), pp. 6945&#x2013;6958). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020c. General Chapters: &#x2329;905&#x232a; Uniformity of Dosage Units. In: United States Pharmacopea (43/38 ed., Vol. 35(3), pp. 7183&#x2013;7187). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020d. General Chapters: &#x2329;1217&#x232a; Tablet Breaking Force. In: United States Pharmacopea (43/38 ed., Vol. 43(6), pp. 8138&#x2013;8141). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020e. General chapters: &#x2329; 1216 &#x232a; Tablet Friability. In: United States Pharmacopea (43/38 ed., Vol. 31(6), pp. 8137). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020f. USP Monographs: Acetaminophen Tablets. In: United States Pharmacopea (43/38 ed., Vol. 43(3), pp. 8266&#x2013;8269). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020g. USP Monographs: Rosuvastatin Tablets. In: United States Pharmacopea (43/38 ed., Vol. 43(2), pp. 3950&#x2013;3956). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference><Reference><Citation>USP/NF, 2020h. USP Monographs: Tadalafil Tablets. In: United States Pharmacopea (43/38 ed., Vol. 38(1), pp. 4205&#x2013;4208). Rockville, MD: United States Pharmacopeial Convention, Inc.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35704597</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>649</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>eabl8503</StartPage><MedlinePgn>eabl8503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abl8503</ELocationID><Abstract><AbstractText>Cyclic GMP-phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract maladaptive cardiac changes triggered by diabetes in some but not all studies. We performed a single-center, 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828) to assess sex differences in cardiac remodeling after PDE5 inhibition in patients with diabetic cardiomyopathy. A total of 122 men and women (45 to 80 years) with long-duration (&gt;3 years) and well-controlled type 2 diabetes mellitus (T2DM; HbA1c &lt; 86 mmol/mol) were selected according to echocardiographic signs of cardiac remodeling. Patients were randomly assigned (1:1) to placebo or oral tadalafil (20 mg, once daily). The primary outcome was to evaluate sex differences in cardiac torsion change. Secondary outcomes were changes in cardiovascular, metabolic, immune, and renal function. At 20 weeks, the treatment-by-sex interaction documented an improvement in cardiac torsion (-3.40&#xb0;, -5.96; -0.84, <i>P</i> = 0.011) and fiber shortening (-1.19%, -2.24; -0.14, <i>P</i> = 0.027) in men but not women. The primary outcome could not be explained by differences in cGMP concentrations or tadalafil pharmacodynamics. In both sexes, tadalafil improved hsa-miR-199-5p expression, biomarkers of cardiovascular remodeling, albuminuria, renal artery resistive index, and circulating Klotho concentrations. Immune cell profiling revealed an improvement in low-grade chronic inflammation: Classic CD14<sup>++</sup>CD16<sup>-</sup> monocytes reduced, and Tie2<sup>+</sup> monocytes increased. Nine patients (14.5%) had minor adverse reactions after tadalafil administration. Continuous PDE5 inhibition could offer a strategy to target cardiorenal complications of T2DM, with sex- and tissue-specific responses. Further studies are needed to confirm Klotho and hsa-miR-199-5p as markers for T2DM complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pofi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7808-5735</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannetta</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feola</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1066-0064</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroendocrinology, Neuromed Institute, IRCCS, 86077 Pozzilli (IS), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galea</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4708-5120</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbagallo</LastName><ForeName>Federica</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2972-370X</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campolo</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badagliacca</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Respiratory Diseases, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbano</LastName><ForeName>Biagio</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciolina</LastName><ForeName>Federica</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5284-3569</Identifier><AffiliationInfo><Affiliation>Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defeudis</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filardi</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5002-0753</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sesti</LastName><ForeName>Franz</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3850-627X</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minnetti</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9091-2809</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizza</LastName><ForeName>Carmine D</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0002-3540-4983</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular and Respiratory Diseases, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqualetti</LastName><ForeName>Patrizio</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5560-1979</Identifier><AffiliationInfo><Affiliation>Medical Statistics and Information Technology, AFaR, Fatebenefratelli Hospital, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caboni</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2448-3767</Identifier><AffiliationInfo><Affiliation>Department of Life and Environmental Sciences, University of Cagliari, 09124 Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbone</LastName><ForeName>Iacopo</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-3108-7527</Identifier><AffiliationInfo><Affiliation>Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francone</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalano</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4208-9691</Identifier><AffiliationInfo><Affiliation>Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzilli</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5090-636X</Identifier><AffiliationInfo><Affiliation>Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenzi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venneri</LastName><ForeName>Mary Anna</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-0687-8135</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianfrilli</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2682-8266</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isidori</LastName><ForeName>Andrea M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-9037-5417</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01803828</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020257" MajorTopicYN="N">Ventricular Remodeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35704597</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abl8503</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35134204</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2472-5625</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>Modern rheumatology case reports</Title><ISOAbbreviation>Mod Rheumatol Case Rep</ISOAbbreviation></Journal><ArticleTitle>Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>183</StartPage><EndPage>188</EndPage><MedlinePgn>183-188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/mrcr/rxac009</ELocationID><Abstract><AbstractText>A 25-year-old woman was admitted to our hospital with severe pulmonary arterial hypertension associated with systemic lupus erythematosus (SLE-PAH). Her mean pulmonary arterial pressure was 56&#x2009;mmHg, and her SLE Disease Activity Index-2&#x2009;K score was 14 on admission. In addition to a strong immunosuppressive regimen, which included steroid pulse therapy followed by high-dose oral prednisolone (1&#x2009;mg/kg) and intravenous cyclophosphamide, an upfront combination of vasodilator therapy, including oral tadalafil, macitentan, and intravenous epoprostenol, was administered in the early phase. Two months later, her mean pulmonary arterial pressure was 29&#x2009;mmHg, and her other haemodynamic markers showed significant improvement. She refused to start life-long intravenous epoprostenol therapy and so was switched to oral selexipag and inhaled iloprost. The transition was successful, and she has experienced no exacerbations of SLE-PAH during the 10&#x2009;months since the onset of pulmonary arterial hypertension. To the best of our knowledge, this is the first report of intravenous epoprostenol being switched to alternative oral and inhaled therapy in a patient with SLE-PAH. In combination with adequate immunosuppressive therapy, it is probably easier to make this transition in patients with SLE-PAH than in those with pulmonary arterial hypertension of a different aetiology. Continuous infusion of epoprostenol can have potentially life-threatening complications and a detrimental effect on the quality of life. Our alternative treatment strategy was successful, and we hope that it will prove beneficial in other cases.</AbstractText><CopyrightInformation>&#xa9; Japan College of Rheumatology 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saiki</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashiwado</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0344-0242</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Taku</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayano</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imabayashi</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Shotaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashioka</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimoto</LastName><ForeName>Yasutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Oita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukata</LastName><ForeName>Mitsuhiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitoma</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arinobu</LastName><ForeName>Yojiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horiuchi</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Oita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niiro</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Education, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mod Rheumatol Case Rep</MedlineTA><NlmUniqueID>101761026</NlmUniqueID><ISSNLinking>2472-5625</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5EXC0E384L</RegistryNumber><NameOfSubstance UI="C523468">selexipag</NameOfSubstance></Chemical><Chemical><RegistryNumber>DCR9Z582X0</RegistryNumber><NameOfSubstance UI="D011464">Epoprostenol</NameOfSubstance></Chemical><Chemical><RegistryNumber>JED5K35YGL</RegistryNumber><NameOfSubstance UI="D016285">Iloprost</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011464" MajorTopicYN="N">Epoprostenol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016285" MajorTopicYN="N">Iloprost</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081029" MajorTopicYN="Y">Pulmonary Arterial Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pulmonary arterial hypertension</Keyword><Keyword MajorTopicYN="N">epoprostenol</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35134204</ArticleId><ArticleId IdType="doi">10.1093/mrcr/rxac009</ArticleId><ArticleId IdType="pii">6520713</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35019157</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0272</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Andrologia</Title><ISOAbbreviation>Andrologia</ISOAbbreviation></Journal><ArticleTitle>Role of shear wave elastography (SWE) in erectile dysfunction patients for evaluation of daily tadalafil treatment outcome.</ArticleTitle><Pagination><StartPage>e14359</StartPage><MedlinePgn>e14359</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/and.14359</ELocationID><Abstract><AbstractText>The purpose of this study was to evaluate and anticipate the outcome of daily use of tadalafil in patients with erectile dysfunction using elastography. 183 volunteers and 183 patients with erectile dysfunction were included. Pretreatment SWE readings for our patients were calculated with a linear probe. IIEF score Q was measured once at the start of the study for volunteers and twice for patients, one prior to the start of tadalafil administration and the other on one year of 5&#xa0;mg daily tadalafil after the second post-washout (one month post-treatment stopped). There was no significant difference between patients and volunteers in mean age or risk factors except in SWE values as mean SWE of volunteers was 14.03&#xa0;&#xb1;&#xa0;1.54&#xa0;kpasc, while mean SWE of patients was 21.278&#xa0;&#xb1;&#xa0;8.228&#xa0;kpasc. The presence of comorbid diabetes, severe disease and pre-SWE &#x2265;23.635 was significantly associated with poor outcome. We conclude that penile SWE could be useful to select probable good responders for a continuous tadalafil use, thus avoiding the unnecessary cost and time in non-responders.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley-VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdelwahab</LastName><ForeName>Khaled M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Urology Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eldery</LastName><ForeName>Mohamed Salah</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Urology Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desoky</LastName><ForeName>Esam</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Urology Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Babouly</LastName><ForeName>Islam M</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0002-7371-9185</Identifier><AffiliationInfo><Affiliation>Urology Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taha</LastName><ForeName>Kareem</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Radiodiagnosis Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saber</LastName><ForeName>Sameh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Radiodiagnosis Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seleem</LastName><ForeName>Mohammed M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Urology Department, Zagazig University, Zagazig, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Andrologia</MedlineTA><NlmUniqueID>0423506</NlmUniqueID><ISSNLinking>0303-4569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054459" MajorTopicYN="Y">Elasticity Imaging Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">impotence</Keyword><Keyword MajorTopicYN="N">shear wave elastography</Keyword><Keyword MajorTopicYN="N">stiffness</Keyword><Keyword MajorTopicYN="N">tadalafil</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>8</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35019157</ArticleId><ArticleId IdType="doi">10.1111/and.14359</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Altinbas, N. K., &amp; Hamidi, N. V. (2018). Penile Doppler ultrasonography and elastography evaluation in patients with erectile dysfunction. Polish Journal of Radiology, 3(83), 491-499. https://doi.org/10.5114/pjr.2018.80301</Citation></Reference><Reference><Citation>Aversa, A., Greco, E., Bruzziches, R., Pili, M., Rosano, G., &amp; Spera, G. (2007). Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. International Journal of Impotence Research, 19(2), 200-207. https://doi.org/10.1038/sj.ijir.3901513</Citation></Reference><Reference><Citation>Aversa, A., Vitale, C., Volterrani, M., Fabbri, A., Spera, G., Fini, M., &amp; Rosano, G. M. (2008). Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabetic Medicine, 25(1), 37-44. https://doi.org/10.1111/j.1464-5491.2007.02298.x</Citation></Reference><Reference><Citation>Brock, G., Ni, X., Oelke, M., Mulhall, J., Rosenberg, M., Seftel, A., D'Souza, D., &amp; Barry, J. (2016). Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. The Journal of Sexual Medicine, 13(5), 860-875. https://doi.org/10.1016/j.jsxm.2016.02.171</Citation></Reference><Reference><Citation>Carneiro, F., &amp; Miranda, E. P. (2018). Penile elastography: current and future applications in sexual medicine. The Journal of Sexual Medicine. 15(6), 816-819.</Citation></Reference><Reference><Citation>Cheng, H., Niu, Z., Xin, F., Yang, L., &amp; Ruan, L. (2020). A new method to quantify penile erection hardness: real-time ultrasonic shear wave elastography. Translational Andrology and Urology. 9(4), 1735-1742.</Citation></Reference><Reference><Citation>Claro, J., Aboim, J., Andrade, E., Alarcon, G., Ortiz, V., Sampaio, F., &amp; Srougi, M. (2005). Histomorphometry of penile smooth muscle fiber in severe erectile dysfunction. Sao Paulo Medical Journal =. Revista Paulista De Medicina, 123(4), 181-186. https://doi.org/10.1590/s1516-31802005000400005</Citation></Reference><Reference><Citation>Cui, A., Xu, L., Mu, J., Tong, M., Peng, C., &amp; Wu, T. (2018). The role of shear wave elastography on evaluation of the rigidity changes of corpus cavernosum penis in venogenic erectile dysfunction. European Journal of Radiology, 103, 1-5. https://doi.org/10.1016/j.ejrad.2018.03.025</Citation></Reference><Reference><Citation>De Berardis, G., Franciosi, M., Belfiglio, M., Di Nardo, B., Greenfield, S., Kaplan, S. H., Pellegrini, F., Sacco, M., Tognoni, G., Valentini, M., &amp; Nicolucci, A. (2002). Quality of Care and Outcomes in Type 2 Diabetes (QuED) Study Group. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care, 25(2), 284-291. https://doi.org/10.2337/diacare.25.2.284</Citation></Reference><Reference><Citation>DeWall, R. J. (2013). Ultrasound elastography: principles, techniques, and clinical applications. Critical Reviews in Biomedical Engineering, 41, 1-19.</Citation></Reference><Reference><Citation>Dorey, G. (2001). Is smoking a cause of erectile dysfunction? A Literature Reviews. British Journal of Nursing, 10(7), 455-465. https://doi.org/10.12968/bjon.2001.10.7.5331</Citation></Reference><Reference><Citation>El-Sakka, A. I., &amp; Tayeb, K. A. (2003). Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients. Journal of Urology, 169(3), 1043-1047. https://doi.org/10.1097/01.ju.0000050080.21839.f9</Citation></Reference><Reference><Citation>Fedele, D., Coscelli, C., Santeusanio, F., Bortolotti, A., Chatenoud, L., Colli, E., Landoni, M., &amp; Parazzini, F. (1998). Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care, 21(11), 1973-1977.</Citation></Reference><Reference><Citation>Fusco, F., Razzoli, E., Imbimbo, C., Rossi, A., Verze, P., &amp; Mirone, V. (2010). A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU International, 105(12), 1634-1639. https://doi.org/10.1111/j.1464-410X.2010.09244.x</Citation></Reference><Reference><Citation>Giuliano, F. A., Leriche, A., Jaudinot, E. O., &amp; de Gendre, A. S. (2004). Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology, 64(6), 1196-1201. https://doi.org/10.1016/j.urology.2004.08.059</Citation></Reference><Reference><Citation>Gonzalez-Cadavid, N. F. (2009). Mechanisms of penile fibrosis. The Journal of Sexual Medicine, 6(3), 353-362. https://doi.org/10.1111/j.1743-6109.2008.01195.x</Citation></Reference><Reference><Citation>Hamidi, N., Altinbas, N. K., Gokce, M. I., Suer, E., Yagci, C., Baltaci, S., &amp; Turkolmez, K. (2017). Preliminary results of a new tool to evaluate cavernous body fibrosis following radical prostatectomy: penile elastography. Andrology, 5(5), 999-1006. https://doi.org/10.1111/andr.12408</Citation></Reference><Reference><Citation>Hatzichristou, D., Gambla, M., Rubio-Aurioles, E., Buvat, J., Brock, G. B., Spera, G., Rose, L., Lording, D., &amp; Liang, S. (2008). Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabetic Medicine, 25(2), 138-146. https://doi.org/10.1111/j.1464-5491.2007.02338.x</Citation></Reference><Reference><Citation>Hauri, D., Spycher, M., &amp; Br&#xfc;hlmann, W. (1983). Erection and priapism: a new physiopathological concept. Urologia Internationalis, 38(3), 138-145. https://doi.org/10.1159/000280878</Citation></Reference><Reference><Citation>Inci, E., Turkay, R., Nalbant, M. O., Yenice, M. G., &amp; Tugcu, V. (2017). The value of shear wave elastography in the quantification of corpus cavernosum penis rigidity and its alteration with age. European Journal of Radiology, 89, 106-110. https://doi.org/10.1016/j.ejrad.2017.01.029</Citation></Reference><Reference><Citation>Jain, V., Yadav, S. S., Jaipal, U., &amp; Tomar, V. (2015). Role of elastography in evaluation of erectile dysfunction and its comparison with colour doppler - a pilot study. Medical Science, 4(11), 402-405.</Citation></Reference><Reference><Citation>Jevtich, M. J., Khawand, N. Y., &amp; Vidic, B. (1990). Clinical significance of ultrastructural findings in the corpora cavernosa of normal and impotent men. Journal of Urology, 143(2), 289-293. https://doi.org/10.1016/s0022-5347(17)39936-6</Citation></Reference><Reference><Citation>Johannes, C. B., Araujo, A. B., Feldman, H. A., Derby, C. A., Kleinman, K. P., &amp; McKinlay, J. B. (2000). Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. Journal of Urology, 163(2), 460-463.</Citation></Reference><Reference><Citation>Kerfoot, W. W., &amp; Carson, C. C. (1991). Pharmacologically induced erections among geriatric men. Journal of Urology, 146(4), 1022-1024. https://doi.org/10.1016/s0022-5347(17)37992-2</Citation></Reference><Reference><Citation>Lee, J. Y., Jung, D. C., Lee, S., Kang, N. G., Oh, Y. T., &amp; Han, K. (2021). Stiffness of the central corpus cavernosum on shear-wave elastography is inversely correlated with the penile rigidity score in patients with erectile dysfunction. The World Journal of Men's Health. 39(1), 123-130.</Citation></Reference><Reference><Citation>Leungwattanakij, S., Bivalacqua, T. J., Usta, M. F., Yang, D. Y., Hyun, J. S., Champion, H. C., Abdel-Mageed, A. B., &amp; Hellstrom, W. J. (2003). Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. Journal of Andrology, 24(2), 239-245. https://doi.org/10.1002/j.1939-4640.2003.tb02668.x</Citation></Reference><Reference><Citation>Lue, T. F. (2000). Erectile dysfunction. New England Journal of Medicine, 342(24), 1802-1813. https://doi.org/10.1056/NEJM200006153422407</Citation></Reference><Reference><Citation>Maio, G., Saraeb, S., &amp; Marchiori, A. (2010). Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. The Journal of Sexual Medicine, 7(6), 2201-2208. https://doi.org/10.1111/j.1743-6109.2010.01783.x</Citation></Reference><Reference><Citation>Malavige, L. S., Jayaratne, S. D., Kathriarachchi, S. T., Sivayogan, S., Fernando, D. J., &amp; Levy, J. C. (2008). Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. The Journal of Sexual Medicine, 5(9), 2125-2134. https://doi.org/10.1111/j.1743-6109.2008.00907.x</Citation></Reference><Reference><Citation>McCulloch, D. K., Campbell, I. W., Wu, F. C., Prescott, R. J., &amp; Clarke, B. F. (1980). The prevalence of diabetic impotence. Diabetologia, 18(4), 279-283.</Citation></Reference><Reference><Citation>McMahon, C. (2004). Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. The Journal of Sexual Medicine, 1(3), 292-300. https://doi.org/10.1111/j.1743-6109.04042.x</Citation></Reference><Reference><Citation>Melman, A., Mason, B., Leung, A. C., &amp; DiSanto, M. E. (2017). Male sexual dysfunction in diabetes mellitus. Principles of Diabetes Mellitus. Springer, Cham, pp. 491-512, https://doi.org/10.1007/978-3-319-18741-9_26</Citation></Reference><Reference><Citation>Molina-Vega, M., Asenjo-Plaza, M., Banderas-Donaire, M. J., Hern&#xe1;ndez-Ollero, M. D., Rodr&#xed;guez-Moreno, S., &#xc1;lvarez-Mill&#xe1;n, J. J., Cabezas-Sanchez, P., Cardona-D&#xed;az, F., Alcaide-Torres, J., Garrido-S&#xe1;nchez, L., Castellano-Castillo, D., Tinahones, F. J., &amp; Fern&#xe1;ndez-Garc&#xed;a, J. C. (2020). Prevalence of and risk factors for erectile dysfunction in young nondiabetic obese men: results from a regional study. Asian Journal of Andrology, 22(4), 372-378. https://doi.org/10.4103/aja.aja_106_19</Citation></Reference><Reference><Citation>Montorsi, F., Briganti, A., Salonia, A., Rigatti, P., Margonato, A., Macchi, A., Galli, S., Ravagnani, P. M., &amp; Montorsi, P. (2003). Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. European Urology, 44(3), 360-364. https://doi.org/10.1016/s0302-2838(03)00305-1</Citation></Reference><Reference><Citation>Moreira, E. D. Jr, Lbo, C. F., Diament, A., Nicolosi, A., &amp; Glasser, D. B. (2003). Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology, 61(2), 431-436. https://doi.org/10.1016/s0090-4295(02)02158-1</Citation></Reference><Reference><Citation>Nunes, K. P., Labazi, H., &amp; Webb, R. C. (2012). New insights into hypertension-associated erectile dysfunction. Current Opinion in Nephrology and Hypertension, 21(2), 163-170. https://doi.org/10.1097/MNH.0b013e32835021bd</Citation></Reference><Reference><Citation>Qiao, X. H., Zhang, J. J., Gao, F., Li, F., Bai, M., Du, L. F., &amp; Xing, J. F. (2017). An experimental study: Quantitatively evaluating the change of the content of collagen fibres in penis with two-dimensional ShearWave&#x2122; Elastography. Andrologia. 49(5). https://doi.org/10.1111/and.12653</Citation></Reference><Reference><Citation>Richards, G., Goldenberg, E., Pek, H., &amp; Gilbert, B. R. (2014). Penile sonoelastography for the localization of a non-palpable, non-sonographically visualized lesion in a patient with penile curvature from Peyronie's disease. The Journal of Sexual Medicine, 11(2), 516-520. https://doi.org/10.1111/jsm.12396</Citation></Reference><Reference><Citation>Sasaki, H., Yamasaki, H., Ogawa, K., Nanjo, K., Kawamori, R., Iwamoto, Y., Katayama, S., &amp; Shirai, M. (2005). Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Research and Clinical Practice, 70(1), 81-89. https://doi.org/10.1016/j.diabres.2005.02.018</Citation></Reference><Reference><Citation>Seftel, A. D., Buvat, J., Althof, S. E., McMurray, J. G., Zeigler, H. L., Burns, P. R., &amp; Wong, D. G. (2009). Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. International Journal of Impotence Research, 21(4), 240-248. https://doi.org/10.1038/ijir.2009.22</Citation></Reference><Reference><Citation>Shabsigh, R., Donatucci, C., Costabile, R., Perelman, M. A., Burns, P., Zeigler, H., &amp; Wong, D. G. (2010). Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. International Journal of Impotence Research, 22(1), 1-8. https://doi.org/10.1038/ijir.2009.29</Citation></Reference><Reference><Citation>Shiina, T., Nitta, N., Ueno, E., &amp; Bamber, J. C. (2002). Real time tissue elasticity imaging using the combined autocorrelation method. Journal of Medical Ultrasonics, 29, 119-128. https://doi.org/10.1007/BF02481234</Citation></Reference><Reference><Citation>Siu, S. C., Lo, S. K., Wong, K. W., Ip, K. M., &amp; Wong, Y. S. (2001). Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabetic Medicine, 18(9), 732-738. https://doi.org/10.1046/j.0742-3071.2001.00557.x</Citation></Reference><Reference><Citation>Tengs, T. O., &amp; Osgood, N. D. (2001). The link between smoking and impotence: two decades of evidence. Preventive Medicine, 32(6), 447-452. https://doi.org/10.1006/pmed.2001.0830</Citation></Reference><Reference><Citation>Turkay, R., Inci, E., Yenice, M. G., &amp; Tugcu, V. (2017). Shear wave elastography: can it be a new radiologic approach for the diagnosis of erectile dysfunction? Ultrasound. 25, 150-155. https://doi.org/10.1177/1742271X17697512</Citation></Reference><Reference><Citation>Wespes, E., Goes, P. M., Schiffmann, S., Depierreux, M., Vanderhaeghen, J. J., &amp; Schulman, C. C. (1991). Computerized analysis of smooth muscle fibers in potent and impotent patients. Journal of Urology, 146(4), 1015-1017. https://doi.org/10.1016/s0022-5347(17)37990-9</Citation></Reference><Reference><Citation>Zhang, J. J., Qiao, X. H., Gao, F., Bai, M., Li, F., Du, L. F., &amp; Xing, J. F. (2015). Smooth muscle cells of penis in the rat: noninvasive quantification with shear wave elastography. BioMed Research International. 2015, 595742. https://doi.org/10.1155/2015/595742</Citation></Reference><Reference><Citation>Zhang, J.-J., Qiao, X.-H., Gao, F., Li, F., Bai, M., Zhang, H.-P., Liu, Y., Du, L.-F., &amp; Xing, J.-F. (2015). A new method of measuring the stiffness of corpus cavernosum penis with ShearWave&#x2122; Elastography. The British Journal of Radiology, 88(1048), 20140671. https://doi.org/10.1259/bjr.20140671</Citation></Reference><Reference><Citation>Zhou, W., Zhang, Y., Li, L., Gao, J., Zheng, H., Huang, M., Zhao, S., Xie, X., Zhang, C., &amp; Zhang, X. (2021). Evaluation of arterial erectile dysfunction using shear wave elastography: A feasibility study. Journal of Ultrasound in Medicine, 40(6), 1209-1216. https://doi.org/10.1002/jum.15502</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33821578</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2055-5822</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>ESC heart failure</Title><ISOAbbreviation>ESC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation.</ArticleTitle><Pagination><StartPage>2419</StartPage><EndPage>2427</EndPage><MedlinePgn>2419-2427</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ehf2.13322</ELocationID><Abstract><AbstractText Label="AIMS">Therapy with phosphodiesterase-5 inhibitors (PDE5Is) after left ventricular assist device (LVAD) implantation has been associated with lower mortality and device thrombosis but increased risk for post-operative and gastrointestinal bleeding. We aimed to evaluate the impact of long-term PDE5Is on the overall bleeding risk after LVAD implantation.</AbstractText><AbstractText Label="METHODS AND RESULTS">We retrospectively included patients who received a continuous-flow LVAD at our site and were prescribed with long-term oral PDE5Is after discharge from the index hospitalization. The primary endpoint was the occurrence of bleeding at 12&#xa0;month follow-up. Secondary endpoints were all-cause death and the combination of bleeding and all-cause death. Our analysis included 109 patients of whom 75 (69%) received long-term PDE5Is. Mean age was 56&#xa0;years, and 85% were male. At 12&#xa0;months, 19 (17%) patients experienced at least one bleeding event. Patients on PDE5Is had higher bleeding rates (23% vs. 6%, P&#xa0;=&#xa0;0.03) and more bleeding events per patient-year (0.32 vs. 0.06, P&#xa0;=&#xa0;0.03) compared with patients not on PDE5Is. While overall bleeding incidence was excessively higher in the PDE5I group, there were no significant differences in the incidence of major bleeding (19% vs. 6%, P&#xa0;=&#xa0;0.08) and gastrointestinal bleeding (11% vs. 3%, P&#xa0;=&#xa0;0.18). Kaplan-Meier analysis revealed higher cumulative incidence of bleeding for the PDE5I group (log rank&#xa0;=&#xa0;0.04) with no difference on all-cause death (log rank&#xa0;=&#xa0;0.67) and the combination of bleeding and all-cause death (log rank&#xa0;=&#xa0;0.13). Hospitalizations for bleeding and their duration were numerically higher in the PDE5I group (0.28 vs. 0.03, P&#xa0;=&#xa0;0.07 and 2.4 vs. 0.2, P&#xa0;=&#xa0;0.07, respectively).</AbstractText><AbstractText Label="CONCLUSIONS">Phosphodiesterase-5 inhibitor treatment after LVAD implantation is associated with increased bleeding risk after LVAD implantation. The safety of long-term PDE5Is in LVAD patients remains unclear and needs to be further clarified in prospective studies with randomized study design.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. ESC Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jakstaite</LastName><ForeName>Aiste-Monika</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luedike</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmack</LastName><ForeName>Bastian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizanis</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riebisch</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weymann</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamler</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruhparwar</LastName><ForeName>Arjang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassaf</LastName><ForeName>Tienush</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papathanasiou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, Essen, 45147, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ESC Heart Fail</MedlineTA><NlmUniqueID>101669191</NlmUniqueID><ISSNLinking>2055-5822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>ESC Heart Fail. 2021 Aug;8(4):2365-2367</RefSource><PMID Version="1">33969639</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Left ventricular assist devices</Keyword><Keyword MajorTopicYN="N">Phosphodiesterase-5 inhibitors</Keyword><Keyword MajorTopicYN="N">Sildenafil</Keyword><Keyword MajorTopicYN="N">Tadalafil</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33821578</ArticleId><ArticleId IdType="pmc">PMC8318463</ArticleId><ArticleId IdType="doi">10.1002/ehf2.13322</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, Naftel DC. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant 2017; 36: 1080&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">28942782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J. A fully magnetically levitated left ventricular assist device&#x2014;final report. N Engl J Med 2019; 380: 1618&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883052</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanasiou M, Pohl J, J&#xe1;nosi RA, Pizanis N, Kamler M, Rassaf T, Luedike P. Colonization with multiresistant bacteria: impact on ventricular assist device patients. Ann Thorac Surg 2018; 105: 557&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">29174784</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32: 157&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23352391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdan R, Mansour H, Nassar P, Saab M. Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor. Artif Organs 2014; 38: 963&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">24689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Klodell CT Jr, Morey TE, Lobato EB, Aranda JM Jr, Staples ED, Schofield RS, Hess PJ, Martin TD, Beaver TM. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007; 83: 68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL, Mathai SC, Thiemann DR, Hassoun PM, Girgis RE, Orens JB. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008; 1: 213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001820</ArticleId><ArticleId IdType="pubmed">19808294</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanasiou M, Ruhparwar A, Kamler M, Rassaf T, Luedike P. Off&#x2010;label use of pulmonary vasodilators after left ventricular assist device implantation: calling in the evidence. Pharmacol Ther 2020: 107619.</Citation><ArticleIdList><ArticleId IdType="pubmed">32599009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrow CT, LaRue SJ, Schilling JD. Intersection of pulmonary hypertension and right ventricular dysfunction in patients on left ventricular assist device support: is there a role for pulmonary vasodilators? Circ Heart Fail 2018; 11: e004255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089581</ArticleId><ArticleId IdType="pubmed">29321132</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazanie P, Hammill BG, Patel CB, Kiernan MS, Cooper LB, Arnold SV, Fendler TJ, Spertus JA, Curtis LH, Hernandez AF. Use of heart failure medical therapies among patients with left ventricular assist devices: insights from INTERMACS. J Card Fail 2016; 22: 672&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237600</ArticleId><ArticleId IdType="pubmed">26892975</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough M, Caraballo C, Ravindra NG, Miller PE, Mezzacappa C, Levin A, Gruen J, Rodwin B, Reinhardt S, van Dijk D, Ali A. Neurohormonal blockade and clinical outcomes in patients with heart failure supported by left ventricular assist devices. JAMA Cardiol 2019; 5: 175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865330</ArticleId><ArticleId IdType="pubmed">31738366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati G, Grandin EW, Kennedy K, Cabezas F, DeNofrio DD, Kociol R, Rame JE, Pagani FD, Kirklin JK, Kormos RL, Teuteberg J. Preimplant phosphodiesterase&#x2010;5 inhibitor use is associated with higher rates of severe early right heart failure after left ventricular assist device implantation an INTERMACS analysis. Circ Heart Fail 2019; 12: 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6624075</ArticleId><ArticleId IdType="pubmed">31181953</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter U, Gambaryan S. cGMP and cGMP&#x2010;dependent protein kinase in platelets and blood cells. In cGMP: Generators, Effectors and Therapeutic Implications; 2009. p 533&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">19089344</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson KE. PDE5 inhibitors&#x2014;pharmacology and clinical applications 20&#xa0;years after sildenafil discovery. Br J Pharmacol 2018; 175: 2554&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003652</ArticleId><ArticleId IdType="pubmed">29667180</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkels R, Klotz T, Sticht G, Englemann U, Klaus W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 2001; 37: 413&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300654</ArticleId></ArticleIdList></Reference><Reference><Citation>Halcox JP, Nour KR, Zalos G, Mincemoyer R, Waclawiw MA, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383570</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HM, Jin S, Jang H, Kim JY, Lee JE, Kim J, Kim HS. Sildenafil reduces neointimal hyperplasia after angioplasty and inhibits platelet aggregation via activation of cGMP&#x2010;dependent protein kinase. Sci Rep 2019; 9: 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533301</ArticleId><ArticleId IdType="pubmed">31123275</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosman&#x2010;Rimon L, Tumiati LC, Fuks A, Jacobs I, Lalonde SD, Cherney DZ, Rao V. Increased cyclic guanosine monophosphate levels and continuous&#x2010;flow left&#x2010;ventricular assist devices: implications for gastrointestinal bleeding. J Thorac Cardiovasc Surg 2016; 151: 219&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">26515873</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">19878532</ArticleId></ArticleIdList></Reference><Reference><Citation>Houston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant 2017; 36: 380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">28169115</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 2011; 123: 2736&#x2013;2747.</Citation><ArticleIdList><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich JD, Gosev I, Patel CB, Joseph S, Katz JN, Eckman PM, Lee S, Sundareswaran K, Kilic A, Bethea B, Soleimani B, Lima B, Uriel N, Kiernan M. The incidence, risk factors, and outcomes associated with late right&#x2010;sided heart failure in patients supported with an axial&#x2010;flow left ventricular assist device. J Heart Lung Transplant 2017; 36: 50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27746085</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SR, Vukelic S, Jorde UP. Bleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy? J Thorac Dis 2016; 8: E1321&#x2013;E1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5107551</ArticleId><ArticleId IdType="pubmed">27867617</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurvits GE, Fradkov E. Bleeding with the artificial heart: gastrointestinal hemorrhage in CF&#x2010;LVAD patients. World J Gastroenterol 2017; 23: 3945&#x2013;3953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5473115</ArticleId><ArticleId IdType="pubmed">28652649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataria R, Jorde UP. Gastrointestinal bleeding during continuous&#x2010;flow left ventricular assist device support state of the field. Cardiol Rev 2019; 27: 8&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">30520778</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliopoulou A, Selzman CH. Stop the LVAD bleeding. J Thorac Dis 2017; 9: E437&#x2013;E439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465108</ArticleId><ArticleId IdType="pubmed">28616303</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T, Kinugawa K, Uriel N. Therapeutic strategy for gastrointestinal bleeding in patients with left ventricular assist device. Circ J 2018; 82: 2931&#x2013;2938.</Citation><ArticleIdList><ArticleId IdType="pubmed">30369592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, Grady KL. The Society of Thoracic Surgeons Intermacs database annual report: evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant 2019; 38: 114&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">30691593</ArticleId></ArticleIdList></Reference><Reference><Citation>Houston BA. Phosphodiesterase&#x2010;5 inhibitor therapy and post&#x2010;left ventricular assist device outcomes the significance of uncertainty. Circ Heart Fail 2019; 12: 1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31181954</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves DS, Blum FE, Huffmyer JL, Kennedy JL, Ahmad HB, Durieux ME, Kern JA. Effects of early inhaled epoprostenol therapy on pulmonary artery pressure and blood loss during LVAD placement. J Cardiothorac Vasc Anesth 2014; 28: 652&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">24103713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo J, Yotti R, Garc&#xed;a&#x2010;Orta R, S&#xe1;nchez&#x2010;Fern&#xe1;ndez PL, Casta&#xf1;o M, Segovia&#x2010;Cubero J, Escribano&#x2010;Sub&#xed;as P, San Rom&#xe1;n JA, Borr&#xe1;s X, Alonso&#x2010;G&#xf3;mez A, Botas J. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double&#x2010;blind, randomized clinical trial. Eur Heart J 2018; 39: 1255&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5905634</ArticleId><ArticleId IdType="pubmed">29281101</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda K, Takayama H, Colombo PC, Jorde UP, Yuzefpolskaya M, Fukuhara S, Mancini DM, Naka Y. Late right heart failure during support with continuous&#x2010;flow left ventricular assist devices adversely affects post&#x2010;transplant outcome. J Heart Lung Transplant 2015; 34: 667&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">25577566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittipibul V, Blumer V, Angsubhakorn N, Hernandez GA, Chaparro S, Tedford RJ, Agarwal R. Phosphodiesterase&#x2010;5 inhibitors and outcomes during left ventricular assist device support: a systematic review and meta&#x2010;analysis. J Card Fail;doi:. Published online ahead of print 29 December 2020; 27: 477&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">33385522</ArticleId></ArticleIdList></Reference><Reference><Citation>Xanthopoulos A, Tryposkiadis K, Triposkiadis F, Fukamachi K, Soltesz EG, Young JB, Wolski K, Blackstone EH, Starling RC. Postimplant phosphodiesterase type 5 inhibitors use is associated with lower rates of thrombotic events after left ventricular assist device implantation. JAHA 2020; 9: e015897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660717</ArticleId><ArticleId IdType="pubmed">32648508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridhar AM, Mukherjee V, Patel DB, Ruiz G, Chawla R, Boyce SW, Najjar SS. Single center experience in the use of sildenafil for right ventricular dysfunction after LVAD implantation. J Heart Lung Transplant 2011; 30: S209&#x2013;S210.</Citation></Reference><Reference><Citation>Netuka I, Iv&#xe1;k P, Tu&#x10d;anov&#xe1; Z, Gregor S, Sz&#xe1;rszoi O, Sood P, Crandall D, Rimsans J, Connors JM, Mehra MR. Evaluation of low&#x2010;intensity anti&#x2010;coagulation with a fully magnetically levitated centrifugal&#x2010;flow circulatory pump&#x2014;the MAGENTUM 1 study. J Heart Lung Transplant 2018; 37: 579&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">29655662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32981502</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-5592</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Current drug targets</Title><ISOAbbreviation>Curr Drug Targets</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>37</EndPage><MedlinePgn>31-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1389450121666200925145347</ELocationID><Abstract><AbstractText Label="BACKGROUND">Phosphodiesterase 5 inhibitors (PDE5I) represent the first-line treatment in the management of post-operative erectile dysfunction (ED) after pelvic oncological surgery. The aim of our study is to evaluate the available evidence on the efficacy of PDE5Is, including new formulations and penile rehabilitation post-pelvic surgery.</AbstractText><AbstractText Label="EVIDENCE ACQUISITION">A systematic review of the literature was performed until May 2020. The following databases were searched: Scopus, Medline and Web of Science. The MeSH search was conducted by combining the following terms: 'erectile dysfunction', 'radical prostatectomy' 'pelvic' 'bladder' 'phosphodiesterase' inhibitors' 'avanafil' 'sildenafil' 'tadalafil' 'lodenafil' 'mirodenafil' 'udenafil' 'vardenafil' 'sublingual' 'orodispersible' 'penile' 'rehabilitation'.</AbstractText><AbstractText Label="EVIDENCE SYNTHESIS">Sildenafil, Tadalafil, vardenafil and Avanafil improve EF compared with placebo in men with all levels of ED severity after radical prostatectomy with good tolerability. No specific recommendations can be suggested regarding the superiority of a drug over the other. The optimal dose, continuous vs. on-demand and duration of treatment, is still under investigation. In vitro and preclinical studies suggest the possible role for lodenafil, mirodenafil and oro-dispersible formulations in patients undergoing oncological pelvic surgery. Few studies demonstrated the efficacy of udenafil in improving ED after rectal surgery or radical prostatectomy. Complete recovery of EF after surgery is still an unmet need in the field of penile rehabilitation after pelvic surgery.</AbstractText><AbstractText Label="CONCLUSION">PDE5Is have a crucial role in the management of post pelvic surgery of ED. New drugs and new formulations have shown excellent results in patients with ED; however, data in patients after surgery is still scarce. Further well designed RCT should clarify the role of these new compounds and oro-dispersible formulations in the management of ED in patients undergoing pelvic surgery.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ospedale Sant'Andrea, Department of Urology 'Sapienza' Univeristy of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tema</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ospedale Sant'Andrea, Department of Urology 'Sapienza' Univeristy of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Nunzio</LastName><ForeName>Cosimo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ospedale Sant'Andrea, Department of Urology 'Sapienza' Univeristy of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Drug Targets</MedlineTA><NlmUniqueID>100960531</NlmUniqueID><ISSNLinking>1389-4501</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Phosphodiesterase 5 inhibitors</Keyword><Keyword MajorTopicYN="N">erectile dysfunction</Keyword><Keyword MajorTopicYN="N">orodispersible</Keyword><Keyword MajorTopicYN="N">pelvic</Keyword><Keyword MajorTopicYN="N">penile rehabilitation</Keyword><Keyword MajorTopicYN="N">radical prostatectomy</Keyword><Keyword MajorTopicYN="N">surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>28</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32981502</ArticleId><ArticleId IdType="doi">10.2174/1389450121666200925145347</ArticleId><ArticleId IdType="pii">CDT-EPUB-110239</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32149476</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0496</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Pediatric pulmonology</Title><ISOAbbreviation>Pediatr Pulmonol</ISOAbbreviation></Journal><ArticleTitle>Implantable LENUS pro pump for treprostinil infusion in three pediatric patients.</ArticleTitle><Pagination><StartPage>1254</StartPage><EndPage>1258</EndPage><MedlinePgn>1254-1258</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.24707</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prostanoid treatment in patients with severe pulmonary arterial hypertension (PAH) has been proven safe and effective. Subcutaneous administration of treprostinil has side effects, which limits their use and acceptance. An implantable pump for continuous intravenous treprostinil infusion has been recently approved. We describe our experience with the implantable pump in three pediatric patients.</AbstractText><AbstractText Label="DESCRIPTION OF CASES">The LENUS pro pump was implanted in three adolescents with severe PAH, who were treated with tadalafil, ambrisentan, and subcutaneous treprostinil. The indication of the Lenus pro pump implantation was the local side effects of subcutaneous treprostinil (pain, inflammation, and local infection) that were not well tolerated and that severely decreased their quality of life. The pump was surgically implanted under general anesthesia.One patient, in functional class IV, suffered postoperative hemodynamic instability and small pneumothorax, &#x2009;requiring an increase in treprostinil dose up to 85&#x2009;ng/kg/min and a decrease 9 days after the pump implantation. The second patient who was discharged 4 days after surgery with treprostinil at 60&#x2009;ng/kg/min reported improvement in his quality of life, but the dose requirement increased up to 92&#x2009;ng/kg/min. After a 21-month follow-up, this patient received a lung transplant. The third patient presented a hematoma at the pump site with no other complications and had a follow-up of 9 months with an improvement in her quality of life.</AbstractText><AbstractText Label="COMMENTS">Implantable pumps for continuous parenteral prostanoid infusion in pediatric patients are an alternative to external pumps, especially when familiar psychological or psychomotor issues hinder the use of external pumps.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xc1;lvarez-Fuente</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2130-7880</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Cardiology, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrido-Lestache</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiology, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivero</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4777-7090</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Cardiology, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Centella</LastName><ForeName>Tomasa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiac Surgery, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamas</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiac Surgery, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Caballero</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Cerro</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Pediatric Cardiology, Ramon y Cajal Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Pulmonol</MedlineTA><NlmUniqueID>8510590</NlmUniqueID><ISSNLinking>1099-0496</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>DCR9Z582X0</RegistryNumber><NameOfSubstance UI="D011464">Epoprostenol</NameOfSubstance></Chemical><Chemical><RegistryNumber>RUM6K67ESG</RegistryNumber><NameOfSubstance UI="C427248">treprostinil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011464" MajorTopicYN="N">Epoprostenol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015918" MajorTopicYN="Y">Infusion Pumps, Implantable</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016040" MajorTopicYN="N">Lung Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">implantable pump</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword><Keyword MajorTopicYN="N">prostanoid treatment</Keyword><Keyword MajorTopicYN="N">pulmonary arterial hypertension</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32149476</ArticleId><ArticleId IdType="doi">10.1002/ppul.24707</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53:1.</Citation></Reference><Reference><Citation>Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007;99(5):696-698.</Citation></Reference><Reference><Citation>Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr. 2011;158(4):584-588.</Citation></Reference><Reference><Citation>Levy M, Del Cerro MJ, Nadaud S, et al. Safety, efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol. 2018;264:153-157.</Citation></Reference><Reference><Citation>Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart. 2007;93(6):739-743.</Citation></Reference><Reference><Citation>McCarthy EK, Ogawa MT, Hopper RK, Feinstein JA, Gans HA. Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy. Pulm Circ. 2018;8(1):2045893218754886.</Citation></Reference><Reference><Citation>Ewert R, Richter MJ, Steringer-Mascherbauer R, et al. Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clin Res Cardiol. 2017;106(10):776-783.</Citation></Reference><Reference><Citation>Kurzyna M, Ma&#x142;aczy&#x144;ska-Rajpold K, Koteja A, et al. An implantable pump Lenus pro(R) in the treatment of pulmonary arterial hypertension with intravenous treprostinil. BMC Pulm Med. 2017;17(1):162.</Citation></Reference><Reference><Citation>Richter MJ, Harutyunova S, Bollmann T, et al. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant. 2018;37(10):1235-1244.</Citation></Reference><Reference><Citation>Desole S, Richter MJ, Heine A, Ewert R. Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension. Pulm Circ. 2019;9(1):2045894018788846.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30929323</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2287-4208</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The world journal of men's health</Title><ISOAbbreviation>World J Mens Health</ISOAbbreviation></Journal><ArticleTitle>Acupuncture for Treatment of Erectile Dysfunction: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>322</StartPage><EndPage>338</EndPage><MedlinePgn>322-338</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5534/wjmh.180090</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the effectiveness and safety of acupuncture for erectile dysfunction (ED).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We searched six major English and Chinese databases included randomized controlled trials (RCTs) testing acupuncture alone or in combination for ED. Dichotomous data were presented as risk ratio (RR) and continuous data were presented as mean difference (MD) both with 95% confidence interval (CI). The Revman (v.5.3) was used for data analyses. Quality of evidence across studies was assessed by the online GRADEpro tool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 22 RCTs, fourteen of them involving psychogenic ED. Most of the included RCTs had high or unclear risk of bias. There was no difference between electro-acupuncture and sham acupuncture with electrical stimulation on the rate of satisfaction and self-assessment (RR, 1.50; 95% CI, 0.71-3.16; 1 trial). Acupuncture combined with tadalafil appeared to have better effect on increasing cure rate (RR, 1.31; 95% CI, 1.00-1.71; 2 trials), and International Index of Erectile Function-5 scores (MD, 5.38; 95% CI, 4.46-6.29; 2 trials). When acupuncture plus herbal medicine compared with herbal medicine alone, the combination therapy showed significant better improvement in erectile function (RR, 1.68; 95% CI, 1.31-2.15; 7 trials). Only two trials reported facial red and dizziness cases, and needle sticking and pruritus cases in acupuncture group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low quality evidence shows beneficial effect of acupuncture as adjunctive treatment for people mainly with psychogenic ED. Safety of acupuncture was insufficiently reported. The findings should be confirmed in large, rigorously designed and well-reported trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Korean Society for Sexual Medicine and Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Bao Yong</ForeName><Initials>BY</Initials><Identifier Source="ORCID">0000-0002-2874-4066</Identifier><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Hui Juan</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-3244-6288</Identifier><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guo Yan</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0002-8012-2379</Identifier><AffiliationInfo><Affiliation>NICM Health Research Institute, Western Sydney University, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Li Yan</ForeName><Initials>LY</Initials><Identifier Source="ORCID">0000-0003-1335-867X</Identifier><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9491-203X</Identifier><AffiliationInfo><Affiliation>NICM Health Research Institute, Western Sydney University, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fei</LastName><ForeName>Yu Tong</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0003-3051-0581</Identifier><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2211-8715</Identifier><AffiliationInfo><Affiliation>NICM Health Research Institute, Western Sydney University, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin Lin</ForeName><Initials>XL</Initials><Identifier Source="ORCID">0000-0003-1455-1682</Identifier><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiao Ying</ForeName><Initials>XY</Initials><Identifier Source="ORCID">0000-0002-4414-0318</Identifier><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jian Ping</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-0320-061X</Identifier><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Integrated Traditional Chinese Medicine and Western Medicine, Guangzhou Medical University, Guangzhou, China. Liujp@bucm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R24 AT001293</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>020468C</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1000061020008</GrantID><Acronym>BUCM</Acronym><Agency>Beijing University of Chinese Medicine</Agency><Country>China</Country></Grant><Grant><GrantID>2016-ZXFZJJ-011</GrantID><Acronym>BUCM</Acronym><Agency>Beijing University of Chinese Medicine</Agency><Country>China</Country></Grant><Grant><GrantID>AT001293</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>World J Mens Health</MedlineTA><NlmUniqueID>101596899</NlmUniqueID><ISSNLinking>2287-4208</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acupuncture</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30929323</ArticleId><ArticleId IdType="pmc">PMC6704310</ArticleId><ArticleId IdType="doi">10.5534/wjmh.180090</ArticleId><ArticleId IdType="pii">37.e10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jardin A, Wagner G, Khoury S, Giuliano F, Goldstein I, Padma-Nathan H, et al. Recommendations of the 1st International Consultation on Erectile Dysfunction, co-sponsored by the World Health Organization (WHO) Plymouth: Health Publications Ltd.; 2000.</Citation></Reference><Reference><Citation>McMahon CG. Erectile dysfunction. Intern Med J. 2014;44:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby M. The circle of lifestyle and erectile dysfunction. Sex Med Rev. 2015;3:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784608</ArticleId></ArticleIdList></Reference><Reference><Citation>Peak TC, Yafi FA, Sangkum P, Hellstrom WJ. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015;20:263&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">25740087</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MY, Liu CT, Chang CC, Chen SY, Huang ST. Overview of the relevant literature on the possible role of acupuncture in treating male sexual dysfunction. Acupunct Med. 2014;32:406&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">25052025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho HG, Sweep CG, Chen X, Rabsztyn PR, Meuleman EJ. The use of acupuncture in the treatment of erectile dysfunction. Int J Impot Res. 1999;11:41&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamloul R, Bella A. Complementary and alternative medicine (CAM) for sexual dysfunction. J Sex Med. 2014;11:1097&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">24697859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin ZH, Ma ZG, Liu CZ. [Study on the mechanism of impotence treated with acupuncture] J Clin Acupunct Moxib. 2004;20:1&#x2013;2. Chinese.</Citation></Reference><Reference><Citation>Cui X, Zhou J, Qin Z, Liu Z. Acupuncture for erectile dysfunction: a systematic review. Biomed Res Int. 2016;2016:2171923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738993</ArticleId><ArticleId IdType="pubmed">26885501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R, Qu Y, Wang T, Wan Y, Xu W. Meta-analysis of clinical effectiveness of the acupuncture treatment for erectile dysfunction. Chin J Hum Sex. 2018;27:82&#x2013;85.</Citation></Reference><Reference><Citation>Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S.  Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet] London: The Cochrane Collaboration; 2011.  [cited 2018 Oct 6].  Available from:  http://handbook-5-1.cochrane.org/</Citation></Reference><Reference><Citation>Engelhardt PF, Daha LK, Zils T, Simak R, K&#xf6;nig K, Pfl&#xfc;ger H. Acupuncture in the treatment of psychogenic erectile dysfunction: first results of a prospective randomized placebo-controlled study. Int J Impot Res. 2003;15:343&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">14562135</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZX, Ren ZX. Clinical observation on acupuncture in treatment of erectile dysfunction with type 2 diabetes. Cap Food Med. 2015;22:66&#x2013;67.</Citation></Reference><Reference><Citation>Li T, Tan Y, Xie ZP, Wang WR, Xie S. [Clinical efficacy observation on moderate-frequency electrical pulse acupoint stimulation combined with tadalafil in treatment of diabetic men with erectile dysfunction] Chin J Hum Sex. 2018;27:21&#x2013;23. Chinese.</Citation></Reference><Reference><Citation>Cui Y, Feng Y, Chen L, Zhou Y, Yang X, He J, et al. [Randomized and controlled research of Chinese drug acupoint injection therapy for erectile dysfunction] Chin Acupunct Moxib. 2007;12:881&#x2013;885. Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">18271227</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan XY. Clinical research of Zhen Yang acupuncture therapy in treating impotence [thesis] Changchun: Changchun University of Chinese Medicine; 2007.</Citation></Reference><Reference><Citation>Aydin S, Ercan M, Ca&#x15f;kurlu T, Ta&#x15f;&#xe7;i AI, Karaman I, Odaba&#x15f; O, et al. Acupuncture and hypnotic suggestions in the treatment of non-organic male sexual dysfunction. Scand J Urol Nephrol. 1997;31:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">9249892</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZL, Wang GW, Pan PK. [61 cases of psychological erectile dysfunction treated by electro acupuncture combined with Traditional Chinese Herb Medicine] J Clin Acupunct Moxib. 2011;27:43&#x2013;44. Chinese.</Citation></Reference><Reference><Citation>Dai EQ, Zhang HW, Liu ZQ. [44 cases of impotence treated with acupuncture combined with Traditional Chinese Medicine] Shaanxi J Tradit Chin Med. 2003;24:66&#x2013;67. Chinese.</Citation></Reference><Reference><Citation>Jiang P, Dai N, Yu XH. Therapeutic observation of acupuncture combined with medication for erectile dysfunction. Shanghai J Acupunct Moxib. 2014;33:408&#x2013;409.</Citation></Reference><Reference><Citation>Jiang XP, Liu XY, Li Q. Clinical observation on effect of acupuncture combined with psychological therapy. Chin Foreign Health Abstr. 2012;9:401&#x2013;402.</Citation></Reference><Reference><Citation>Lin XL, Deng PH, Yuan JX. Clinical research on treatment of erectile dysfunction with integrative traditional Chinese medicine and acupuncture. Chin J Hum Sex. 2005;14:8&#x2013;10.</Citation></Reference><Reference><Citation>Liu K, Zeng CH, Ding JY. [Effect of acupoint injection combined with small dose of tadalafil for functional erectile dysfunction] Modern Tradit Chin Med. 2016;36:50&#x2013;51. Chinese.</Citation></Reference><Reference><Citation>Liu XJ. Eight liao points warming needle moxibustion in the treatment of impotence 31 cases. Guangming J Chin Med. 2017;32:2227&#x2013;2229.</Citation></Reference><Reference><Citation>Shan YH. Analysis of curative effects of sexual impotence treated by elongated needle and Chinese herb. Shanghai J Acupunct Moxib. 2001;2:14&#x2013;15.</Citation></Reference><Reference><Citation>Xie DB. Clinical efficacy observation on acupuncture combined with TCM medicine in treatment of male erectile dysfunction. J Hubei College Tradit Chin Med. 2016;18:29&#x2013;31.</Citation></Reference><Reference><Citation>Ye P, Chen SY. [Observation effect of acupuncture combined with Huan Shao capsule for erectile dysfunction] J Pract Tradit Chin Med. 2017;33:21. Chinese.</Citation></Reference><Reference><Citation>Jia JB. Clinical observation on the clinical efficacy of acupuncture and moxibustion combined with drug therapy in the treatment of functional ED [thesis] Wulumuqi: Xinjiang Medical University; 2018.</Citation></Reference><Reference><Citation>Yu WX, Liu SM, Sun N, Yang LJ, Zhang YY. Clinical observation of press-needling combined with sildenafil in the treatment of erectile dysfunction. J Clin Acupunct Moxib. 2018;34:27&#x2013;30.</Citation></Reference><Reference><Citation>Cao YH, Guo XJ, Cheng YZ. [Treatment of impotence with deficiency of kidney-yang by Chinese medicine and acupuncture] Tradit Chin Med Res. 2007;20:42&#x2013;43. Chinese.</Citation></Reference><Reference><Citation>Cheng YZ, Cao YH. [Acupuncture at the point of zhibian (BL54) plus Traditional Chinese Herb Medicine in treating 32 cases of impotence due to deficiency of kidney yang] Tradit Chin Med Res. 2009;22:61&#x2013;62. Chinese.</Citation></Reference><Reference><Citation>Ding SL, Zhang FG, Yuan ZJ, Li YF, Qin GZ. [Clinical observation on 88 cases of erectile dysfunction treated by acupuncture combined with medicine] Yunnan J Tradit Chin Med Materia Medica. 2012;33:50&#x2013;51. Chinese.</Citation></Reference><Reference><Citation>Yang X, Tian BK. [20 cases of impotence treated with acupuncture combined with Traditional Chinese Herb Medicine] J Clin Acupunct Moxib. 2008;24:27&#x2013;28. Chinese.</Citation></Reference><Reference><Citation>Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical trial registration: looking back and moving ahead. N Engl J Med. 2007;356:2734&#x2013;2736.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30801851</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1442-2042</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of urology : official journal of the Japanese Urological Association</Title><ISOAbbreviation>Int J Urol</ISOAbbreviation></Journal><ArticleTitle>Tadalafil improves bladder dysfunction and object recognition in rats with pelvic venous congestion.</ArticleTitle><Pagination><StartPage>578</StartPage><EndPage>585</EndPage><MedlinePgn>578-585</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/iju.13932</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To examine the effects of tadalafil on bladder function and object recognition ability in rats with alterations in urinary frequency and locomotor activity as a result of pelvic venous congestion.</AbstractText><AbstractText Label="METHODS">A total of 48 female rats were divided into three groups (sham, pelvic venous congestion and pelvic venous congestion/tadalafil groups). In the pelvic venous congestion and pelvic venous congestion/tadalafil groups, the bilateral common iliac veins and uterine veins were ligated under anesthesia. Rats in the pelvic venous congestion/tadalafil group received a diet containing tadalafil, and the other rats were fed a normal diet. After 4&#xa0;weeks, rats underwent analysis of voiding behavior, locomotor activity, a novel object recognition test, continuous cystometry, measurement of plasma monoamines, and measurement of plasma and urinary nitric oxide metabolites. Expression of nitric oxide synthase messenger ribonucleic acid in the bladder wall was also assessed, along with histological examination of the bladder.</AbstractText><AbstractText Label="RESULTS">Rats with pelvic venous congestion showed a higher urinary frequency, lower locomotor activity, and lower plasma and urinary nitric oxide levels than sham rats. The bladder wall endothelial nitric oxide synthase messenger ribonucleic acid level was low and object recognition was impaired. Pelvic venous congestion/tadalafil rats showed improvement in locomotor activity, bladder function and object recognition compared with pelvic venous congestion rats, as well as elevation of plasma and urinary nitric oxide, plasma monoamines, and bladder neuronal nitric oxide synthase messenger ribonucleic acid expression. Bladder wall vascularity was greater in pelvic venous congestion/tadalafil rats compared with sham rats.</AbstractText><AbstractText Label="CONCLUSIONS">In rats with pelvic venous congestion, tadalafil might improve bladder function and the general condition by increasing blood flow to the bladder and brain, and by increasing dopamine levels.</AbstractText><CopyrightInformation>&#xa9; 2019 The Japanese Urological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishijima</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Southern Knights' Laboratory, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugaya</LastName><ForeName>Kimio</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Southern Knights' Laboratory, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadekawa</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Southern Knights' Laboratory, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashitomi</LastName><ForeName>Katsuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Southern Knights' Laboratory, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Institute for Animal Experiments, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Urol</MedlineTA><NlmUniqueID>9440237</NlmUniqueID><ISSNLinking>0919-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064804">Urological Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052248">Nitric Oxide Synthase Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052250">Nitric Oxide Synthase Type III</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496322">Nos1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496316">Nos3 protein, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Urol. 2019 May;26(5):585-586</RefSource><PMID Version="1">30854710</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006940" MajorTopicYN="N">Hyperemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052248" MajorTopicYN="N">Nitric Oxide Synthase Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052250" MajorTopicYN="N">Nitric Oxide Synthase Type III</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001743" MajorTopicYN="N">Urinary Bladder</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014554" MajorTopicYN="N">Urination</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014570" MajorTopicYN="N">Urologic Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064804" MajorTopicYN="N">Urological Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dopamine</Keyword><Keyword MajorTopicYN="N">nitric oxide</Keyword><Keyword MajorTopicYN="N">pelvic venous congestion</Keyword><Keyword MajorTopicYN="N">tadalafil</Keyword><Keyword MajorTopicYN="N">urinary frequency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30801851</ArticleId><ArticleId IdType="doi">10.1111/iju.13932</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30258189</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>60</EndPage><MedlinePgn>57-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41443-018-0076-9</ELocationID><Abstract><AbstractText>The FDA approval of Viagra (sildenafil) for the on demand treatment of erectile dysfunction (ED) through relaxation of the corporal and cavernosal vascular smooth muscle that results in an increase in blood flow to the corporal tissues stemmed from 2 decades of research, mainly at academic centers. This culminated in the finding of the nitric oxide/cGMP pathway as the mediator of penile erection, followed by some years of basic studies and clinical validation at Pfizer. Further on, new translational laboratory and animal research from our group initiated a second phase when we proposed an alternative therapeutic schedule and mechanism of action for PDE5 inhibitors (PDE5i) in both corporal veno-occlusive dysfunction (CVOD) and Peyronie's disease (PD), specifically, continuous long-term administration (CLTA) to achieve sustained levels of cGMP within the penis. Due to the extended half-life of the long-acting PDE5i, tadalafil, this new alternative encompasses preferentially daily administration, although shorter half-life PDE5i, like sildenafil and vardenafil work too, depending on the duration, dose, and frequency of their administration This novel use was initially supported by showing the antifibrotic/antioxidant effects of nitric oxide and cGMP, produced by the induction of iNOS, as a mechanism of defense against collagen deposition in the localized fibrotic plaque of PD in an avascular tissue, the tunica albuginea. Our studies on iNOS and the progressive diffuse fibrosis occurring in the smooth muscle in CVOD, led to proposing the CLTA of PDE5i for maintaining sustained cGMP levels both in PD and in CVOD in order to halt or regress the penile fibrosis. In CVOD, we showed that PDE5i protect the corporal smooth muscle and reduce myofibroblast activation and number, counteracting the underlying corporal tissue pathology that causes CVOD, and potentially ameliorating long-term CVOD or even curing it. This review is focused on this novel PDE5i anti-fibrotic therapeutic concept.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez-Cadavid</LastName><ForeName>N F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Division of Urology, Harbor-UCLA Medical Center, Torrance, CA, USA. ncadavid@ucla.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Los Angeles Biomedical Research Institute, Torrance, CA, USA. ncadavid@ucla.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ncadavid@ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajfer</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>H2D2X058MU</RegistryNumber><NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001157" MajorTopicYN="N">Arterial Occlusive Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010411" MajorTopicYN="N">Penile Induration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="N">Translational Research, Biomedical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30258189</ArticleId><ArticleId IdType="doi">10.1038/s41443-018-0076-9</ArticleId><ArticleId IdType="pii">10.1038/s41443-018-0076-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29436260</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2376-1032</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of managed care &amp; specialty pharmacy</Title><ISOAbbreviation>J Manag Care Spec Pharm</ISOAbbreviation></Journal><ArticleTitle>Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.</ArticleTitle><Pagination><StartPage>834</StartPage><EndPage>842</EndPage><MedlinePgn>834-842</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18553/jmcp.2018.17391</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite multiple treatment options, the prognosis of pulmonary arterial hypertension (PAH) remains poor. PAH patients experience a high economic burden due to comorbidities, hospitalizations, and medication costs. Although combination therapy has been shown to reduce hospitalizations, the relationship between treatment, health care utilization, and costs remains unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To provide a characterization of health care utilization and costs in real-world settings by comparing periods before and after initiating PAH-specific treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study identified PAH patients in the Truven Health MarketScan Commercial and Medicare Supplemental Databases between 2010 and 2014 who initiated treatment with endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5Is), or soluble guanylate cyclase (sGC) stimulators. The index date was the date of the first PAH pharmacy claim. We included patients with &#x2265; 2 medical claims with diagnoses for PAH (ICD-9-CM: 416.0, 416.8) or PAH-related conditions and continuous enrollment in medical and pharmacy benefits for the 6 months before and after the index date. Treatment patterns were assessed at the drug class level (ERAs, PDE-5Is, sGC stimulators, and prostacyclins) from outpatient pharmacy claims during the 6-month post-index period. All-cause and PAH-related utilization and costs were measured. McNemar's and paired t-tests were used to compare patients' health care resource utilization and costs in the 6-month pre- and posttreatment periods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3,908 patients met the selection criteria. The study sample was 63% female with a mean age of 63 &#xb1; 15 years. Only 5% of patients began initial combination therapy for PAH, defined as claims for &#x2265; 2 medication classes within the first 30 days of treatment. Treatment interruption (&#x2265; 30-day gap in days supply) of any PAH-specific medication was observed in 38% of patients. Compared with the 6-month pre-index period, the proportion of patients in the 6-month post-index period with any inpatient admission decreased, 42% versus 30% (P &lt; 0.001). In addition, PAH-related inpatient admissions decreased in the 6-month post-index period from 7% to 3% (P &lt; 0.001). After treatment initiation, patients' nonpharmacy medical costs decreased from $48,200 (SD = $117,686) to $33,962 (SD = $90,294; P &lt; 0.001), mainly attributable to reduced inpatient costs. However, total average medical costs including pharmacy costs remained comparable after treatment initiation (pre-index period = $51,455 vs. post-index period = $53,923; P = 0.213).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study found that while patients' PAH-related pharmacy costs increased after treatment initiation, the increase was offset by reduced inpatient utilization; therefore, total health care costs remained constant. While the majority of patients in this study were treated with monotherapy, the recently completed AMBITION study indicated that initial combination therapy with ambrisentan plus tadalafil reduced PAH-related hospitalizations compared with initial monotherapy with either of these agents. Future cost analyses of patients treated with combination therapy will be required to determine the economic effect of initial combination therapy.</AbstractText><AbstractText Label="DISCLOSURES" NlmCategory="BACKGROUND">This study was sponsored and funded by Gilead Sciences. Ozbay is an employee of Gilead Sciences. At the time that this project and manuscript were developed, Lazarus was an employee of Gilead Sciences and may own stock/stock options. Riehle, Montejano, and Lenhart are employees of Truven Health Analytics, an IBM company, which received funding from Gilead Sciences to conduct this study. Burger and White do research with, and are paid consultants for, Gilead Sciences; they do not own equity and received no personal compensation for the work here. Burger also reports consultancy and advisory board work for Actelion Pharmaceuticals and grants from Gilead Sciences, Actelion Pharmaceuticals, Bayer, and United Therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burger</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>1 Mayo Clinic, Jacksonville, Florida, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozbay</LastName><ForeName>A Burak</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>3 Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarus</LastName><ForeName>Howard M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>3 Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riehle</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>4 Truven Health Analytics, an IBM company, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montejano</LastName><ForeName>Leslie B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>4 Truven Health Analytics, an IBM company, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenhart</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>4 Truven Health Analytics, an IBM company, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>R James</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>2 University of Rochester Medical Center; Rochester, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Manag Care Spec Pharm</MedlineTA><NlmUniqueID>101644425</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29436260</ArticleId><ArticleId IdType="doi">10.18553/jmcp.2018.17391</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28977106</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1806-9282</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Revista da Associacao Medica Brasileira (1992)</Title><ISOAbbreviation>Rev Assoc Med Bras (1992)</ISOAbbreviation></Journal><ArticleTitle>Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>692</EndPage><MedlinePgn>689-692</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/1806-9282.63.08.689</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0104-42302017000800689</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The pathogenesis of recurrent priapism is currently being investigated based on the regulation of the phosphodiesterase 5 (PDE5) enzyme. We explored the daily use of PDE5 inhibitors to treat and prevent priapism recurrences.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We administered PDE5 inhibitors using a long-term therapeutic regimen in seven men with recurrent priapism, with a mean age of 29.2 years (range 21 to 35 years). Six men (85.7%) had idiopathic priapism recurrences and one man (24.3%) had sickle cell disease-associated priapism recurrences. Tadalafil 5 mg was administered daily. The mean follow-up was 6.6 months (range 3 to 12 months).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Daily long-term oral PDE5 inhibitor therapy alleviated priapism recurrences in all patients. Five (71.4%) had no episodes of priapism and two (28.6%) referred decrease in their episodes of priapism. All patients referred improvement in erectile function.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest the hypothesis that PDE5 dysregulation exerts a pathogenic role for both sickle cell disease-associated priapism and for idiopathic priapism, and that it offers a molecular target for the therapeutic management of priapism. These preliminary observations suggest that continuous long-term oral PDE5 inhibitor therapy may treat and prevent recurrent priapism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nardozza</LastName><ForeName>Archimedes</ForeName><Initials>A</Initials><Suffix>Junior</Suffix><AffiliationInfo><Affiliation>Associate Professor of Urology, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo (Unifesp), S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrini</LastName><ForeName>Marcelo Rodrigues</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>PhD in Medicine and Assistant Professor of Urology, Escola Paulista de Medicina, Unifesp, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Assoc Med Bras (1992)</MedlineTA><NlmUniqueID>9308586</NlmUniqueID><ISSNLinking>0104-4230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28977106</ArticleId><ArticleId IdType="doi">10.1590/1806-9282.63.08.689</ArticleId><ArticleId IdType="pii">S0104-42302017000800689</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27114197</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases.</ArticleTitle><Pagination><StartPage>860</StartPage><EndPage>875</EndPage><MedlinePgn>860-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsxm.2016.02.171</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(16)00351-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Various factors play a role in the development of erectile dysfunction (ED).</AbstractText><AbstractText Label="AIM">To provide a descriptive comparison of erectile function response for tadalafil on-demand (PRN) and once-daily (OAD) dosing regimens in patients with common comorbid conditions, treatments, or risk factors that can be considered when treating ED.</AbstractText><AbstractText Label="METHODS">In total, 17 PRN and 4 OAD placebo-controlled studies were included in the integrated database in these pooled analyses. Data were analyzed from patients treated with placebo, tadalafil 10 mg (low dose), and 20&#xa0;mg (high dose) for the PRN studies and placebo, tadalafil 2.5 mg (low dose), and 5 mg (high dose) for the OAD studies.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The effects of tadalafil were measured using the International Index of Erectile Function administered from baseline to week 12. A descriptive comparison of the efficacy of tadalafil PRN vs OAD was examined in the clinical populations.</AbstractText><AbstractText Label="RESULTS">Baseline characteristics of 4,354 men were comparable between the PRN and OAD groups, with differences seen only in the variables of race, body mass index (BMI) of at least 30 kg/m(2), and alcohol use. Tadalafil was efficacious at improving erectile function for all clinical populations, except for the low-dose OAD group, which demonstrated a weaker effect vs placebo than the high-dose OAD group, and the low- and high-dose PRN groups vs placebo for patients with BMI of at least 30 kg/m(2) for patients without a cardiovascular disorder, smokers, patients with ED duration shorter than 1 year, and patients without previous phosphodiesterase type 5 inhibitor use. Tadalafil was efficacious for patients with or without diabetes mellitus, arterial hypertension, hyperlipidemia, and alcohol use at baseline.</AbstractText><AbstractText Label="CONCLUSION">Tadalafil OAD and PRN regimens showed efficacy in patients with ED. No clinical populations of patients with ED seemed to benefit overwhelmingly from one dose regimen over the other.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Western University, Canadian Urological Association, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oelke</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulhall</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Matt</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mid Michigan Health Centers, Jackson, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seftel</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cooper Medical School of Rowan University, Camden, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Souza</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>inVentiv Health Company, LLC, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Basingstoke, Hampshire, UK. Electronic address: jbarry@lilly.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="Y">Patient Preference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data Pooling</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Phosphodiesterase Type 5 Inhibitors</Keyword><Keyword MajorTopicYN="N">Tadalafil</Keyword><Keyword MajorTopicYN="N">Treatment Efficacy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27114197</ArticleId><ArticleId IdType="mid">NIHMS860390</ArticleId><ArticleId IdType="pmc">PMC5411983</ArticleId><ArticleId IdType="doi">10.1016/j.jsxm.2016.02.171</ArticleId><ArticleId IdType="pii">S1743-6095(16)00351-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">10925098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca J, Tomada N, Magalh&#xe3;es A, et al. Effect of aging and cardiovascular risk factors on receptor tie1 expression in human erectile tissue. J Sex Med. 2015;12:876&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">25487286</ArticleId></ArticleIdList></Reference><Reference><Citation>Glina S, Sharlip ID, Hellstrom WJ. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med. 2013;10:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">22971247</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen PE, Ettala O, Kautiainen H, et al. Factors modifying the effect of blood pressure on erectile function. J Hypertens. 2015;33:975&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">25668346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med. 2004;1:35&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422981</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes VJ, Anderson RA, George JT. How does obesity affect fertility in men&#x2014;and what are the treatment options? Clin Endocrinol (Oxf) 2015;82:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">25138694</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof SE, O&#x2019;Leary MP, Cappelleri JC, et al. US and International SEAR Study Group. Self-esteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction: results of two double-blind, placebo-controlled trials. J Gen Intern Med. 2006;21:1069&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1831645</ArticleId><ArticleId IdType="pubmed">16836626</ArticleId></ArticleIdList></Reference><Reference><Citation>Althof S. Sexual therapy in the age of pharmacotherapy. Annu Rev Sex Res. 2006;17:116&#x2013;132.</Citation></Reference><Reference><Citation>Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710291</ArticleId></ArticleIdList></Reference><Reference><Citation>Brock G, Chan J, Carrier S, et al. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. BJU Int. 2007;99:376&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">17155989</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man&#x2019;s inability to have sex? J Sex Med. 2014;11:347&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251371</ArticleId></ArticleIdList></Reference><Reference><Citation>Briganti A, Salonia A, Gallina A, et al. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol. 2005;2:239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and metaanalysis. Ann Intern Med. 2009;151:650&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">19884626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KK, Jiann BP, Lin JS, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med. 2004;1:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422975</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi HK, Ahn TY, Kim JJ, et al. A double-blind, randomised-placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res. 2003;15:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12789384</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo YL, Zhu JC, Pan TM, et al. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol. 2006;13:721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">16834650</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip WC, Chiang HS, Mendoza JB, et al. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl. 2006;8:685&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzichristou D, Gambla M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25:138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">18290855</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16766116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajfer J, Aliotta PJ, Steidle CP, et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007;19:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16871272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Aurioles E, Kim ED, Rosen RC, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009;6:1314&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">19473285</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel AD, Buvat J, Althof SE, et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res. 2009;21:240&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">19536128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Aurioles E, El-Meliegy A, Abdulwahed S, et al. Decision tree analyses of key patient characteristics in Middle Eastern/ North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction. Curr Med Res Opin. 2015;31:367&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">25068906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag A, Ni X, Althof SE, et al. Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res. 2014;26:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23864107</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns PR, Rosen RC, Dunn M, et al. Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. J Sex Med. 2015;12:720&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">25615445</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int. 2004;93:1276&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180622</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoumal R, Chen J, Kula K, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol. 2004;46:362&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">15306109</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, Brock GB, Kula K, et al. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function men with erectile dysfunction but na&#xef;ve to phosphodiesterase type 5 inhibitors. J Androl. 2012;33:1305&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pubmed">22790642</ArticleId></ArticleIdList></Reference><Reference><Citation>Brock G, Montorsi F, Costa P, et al. Effect of tadalafil once daily on penile length loss and morning erections in patients after bilateral nerve-sparing radical prostatectomy: results from a randomized controlled trial. Urology. 2015;85:1090&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">25813656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamshidian H, Borhan A, Kooraki S, et al. Evaluation of the efficacy of once-daily use of tadalafil vs on-demand use. Is there a cumulative effect? J Pak Med Assoc. 2012;62:1195&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pubmed">23866410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DH, Lee JY, Chung JH, et al. Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract. 2012;66:813&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">22805273</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YX, Zhou HB, Peng SL, et al. Effects of tadalafil on erectile dysfunction: on-demand versus once-daily dosing. Zhonghua Nan Ke Xue. 2012;18:472&#x2013;474. in Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">22741449</ArticleId></ArticleIdList></Reference><Reference><Citation>Porst H, Gacci M, B&#xfc;ttner H, et al. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol. 2014;65:455&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Allen KR, Ni X, et al. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011;60:1010&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">21855209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis RW, Sadovsky R, Eardley I, et al. The efficacy of tadalafil in clinical populations. J Sex Med. 2005;2:517&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16422847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cialis (LY450190)  [Accessed March 24, 2016];Clinical study results for Cialis (LY450190)  Available at:  http://lillytrials.com/results/cialis.pdf.</Citation></Reference><Reference><Citation>Montorsi F, Aversa A, Moncada I, et al. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are na&#xef;ve to PDE5 inhibitors. J Sex Med. 2011;8:2617&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">21707928</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo AB, Allen KR, Ni X, et al. Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. J Sex Med. 2012;9:169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">21981744</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile function. Urology. 1997;49:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171:1797&#x2013;1803.</Citation><ArticleIdList><ArticleId IdType="pubmed">21911624</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis LO, Favaro WJ, Barreiro GC, et al. Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. Int J Androl. 2010;33:736&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">20039972</ArticleId></ArticleIdList></Reference><Reference><Citation>Harte CB. Concurrent relations among cigarette smoking status, resting heart rate variability, and erectile response. J Sex Med. 2014;11:1230&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">24576257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac JR, Labbate C, Ramasamy R, et al. Effects of cigarette smoking on erectile dysfunction. Andrologia. 2015;47:1087&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485976</ArticleId><ArticleId IdType="pubmed">25557907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabsigh R, Fishman IJ, Schum C, et al. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology. 1991;38:227&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1887536</ArticleId></ArticleIdList></Reference><Reference><Citation>Namiki S, Kwan L, Kagawa-Singer M, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer Prostatic Dis. 2008;11:298&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909566</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26428642</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1124-3562</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica</Title><ISOAbbreviation>Arch Ital Urol Androl</ISOAbbreviation></Journal><ArticleTitle>Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients.</ArticleTitle><Pagination><StartPage>210</StartPage><EndPage>213</EndPage><MedlinePgn>210-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4081/aiua.2015.3.210</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We explored the safety of Tadalafil once-daily treatment for 12 week and its effects on semen quality in a clinical subpopulation of men with psychogenic erectile dysfunction (ED).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Twenty-seven men, between 19 and 35 years, unaware of their fertility status, suffering from psychogenic ED were enrolled. The examination of the seminal fluid was performed twice before administration of Tadalafil and twice after three months of continuous daily administration of Tadalafil 5 mg. The volume of the seminal fluid, the concentration of sperm, the concentration of sperm with type "a+b" motility, the concentration of sperm with type "a" motility, the concentration of normal sperm were taken into consideration. The results before treatment with Tadalafil (T0) and after 3 months of treatment (T3m) were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The administration of once-daily Tadalafil 5mg, brings to an average increase of the total number of sperm cells, both total and fast motility (type a) and the percentage of nemasperms, and to an average increase of semen volume of only 0.41 ml. These quantitative and qualitative improvements of the seminal fluid resulted statistically significant as regard motility, nemasperm percentage and seminal fluid volume. No unespected safety findings were observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tadalafil administration improves the quality of sperm cells and seminal fluid: in particular motility, percentage of nemasperms and volume of seminal fluid. We emphasize the safety of the once-daily treatment with tadalafil 5mg and the positive effects on spermatogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corvasce</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit of Urology, "L. Bonomo" Hospital, ASL BAT, Andria; Centre of Andrology and Reproductive Pro.Andr&#xf2;s certified ISO 9001-2008 certified SIA. peppealbino@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albino</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Leonetti</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Buonomo</LastName><ForeName>Agnese Filomena</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Marucco</LastName><ForeName>Ettore Cirillo</ForeName><Initials>EC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Arch Ital Urol Androl</MedlineTA><NlmUniqueID>9308247</NlmUniqueID><ISSNLinking>1124-3562</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013094" MajorTopicYN="N">Spermatozoa</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26428642</ArticleId><ArticleId IdType="doi">10.4081/aiua.2015.3.210</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25890543</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>193</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J Urol</ISOAbbreviation></Journal><ArticleTitle>Re: Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke.</ArticleTitle><Pagination><StartPage>1324</StartPage><EndPage>1325</EndPage><MedlinePgn>1324-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2015.01.052</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5347(15)00073-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seftel</LastName><ForeName>Allen D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Acta Neurol Scand. 2014 Dec;130(6):380-6</RefSource><PMID Version="1">25208597</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25890543</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2015.01.052</ArticleId><ArticleId IdType="pii">S0022-5347(15)00073-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25588959</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5489</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>International journal of impotence research</Title><ISOAbbreviation>Int J Impot Res</ISOAbbreviation></Journal><ArticleTitle>Prospective evaluation of early postoperative male and female sexual function after radical prostatectomy with erectile nerves preservation.</ArticleTitle><Pagination><StartPage>69</StartPage><EndPage>74</EndPage><MedlinePgn>69-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ijir.2014.36</ELocationID><Abstract><AbstractText>Prostate cancer screening has led to the diagnosis of localized prostate cancer in increasingly young and sexually active men. Accordingly, the impact of cancer treatment on sexual function is gaining more attention. To prospectively evaluate the impact of radical prostatectomy (RP) on male, female and conjugal sexual function. Patients were prospectively assessed by an urologist and a sexologist before and 6 months after robot-assisted laparoscopic RP (RALP). RALP was performed with uni- or bilateral neurovascular bundle preservation by a single surgeon. Postoperatively, all patients were prescribed tadalafil 20 mg, 3 times a week during 6 months. Male and female sexual functions were evaluated by using the International Index of Erectile Function (IIEF-5), the Female Sexual Function Index (FSFI) and the Lock-Wallace Marital Adjustment Test (MAT). Continuous variables were analyzed with rank-sum and t-tests, as needed, and categorical variables with chi-squared tests. All tests were two-sided, with a P-value &#x2a7d; 0.05 considered significant. Twenty-one couples were included. Mean patient male and female age was 62.4 and 60.7 years, respectively. Bilateral nerve sparing was performed in 12/21 (57%) patients. Median preoperative IIEF-5 was 20/25, corresponding to mild erectile dysfunction (ED). Median preoperative FSFI and MAT were both within normal range (28/36 and 114/158, respectively). Six months following surgery, both IIEF-5 (11/25) and FSFI (25/36) had significantly dropped (P=0.007 and 0.003, respectively). Postoperative decreases in IIEF-5 and FSFI scores were associated within couples. MAT scores (115/158), however, remained unaffected by RALP, showing an unmodified relationship satisfaction postoperatively. Finally, bilateral nerve sparing surgery preserved not only male but also female sexual function. This study shows that the expected short-term post-RALP ED is associated with a worsening of female sexual function, whereas nerve sparing surgery has a protective effect on both the patient's and his partner's sexual function with a significant effect of bilateral over unilateral neurovascular bundle preservation. Furthermore, we found that conjugal complicity remains stable throughout the first semestrial postoperative period despite the decrease in sexual function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>S-N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Division of Urologic Surgery, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirth</LastName><ForeName>G J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Division of Urologic Surgery, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayor</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Urologic Surgery, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollini</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sexology Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi-Demicheli</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sexology Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iselin</LastName><ForeName>C E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Urologic Surgery, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Impot Res</MedlineTA><NlmUniqueID>9007383</NlmUniqueID><ISSNLinking>0955-9930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="Y">innervation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="N">Personal Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012747" MajorTopicYN="N">Sexual Partners</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25588959</ArticleId><ArticleId IdType="doi">10.1038/ijir.2014.36</ArticleId><ArticleId IdType="pii">ijir201436</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Urol Nurs. 2003 Aug;23(4):279-85</Citation><ArticleIdList><ArticleId IdType="pubmed">14552074</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1977 Jun;45(3):494-5</Citation><ArticleIdList><ArticleId IdType="pubmed">864068</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2011 Sep;12(9):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21821474</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cancer Care (Engl). 2010 Mar;19(2):234-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19686355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2010 Dec;7(12):3984-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20722784</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Braz J Urol. 2009 Nov-Dec;35(6):673-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20028573</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2009;15(30):3496-501</Citation><ArticleIdList><ArticleId IdType="pubmed">19860695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2009 Feb;181(2):731-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19091349</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2010 Feb;105(3):382-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19747355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15841702</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2010 Jun;57(6):945-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20181424</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 2006 Mar;97(3):467-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16469009</ArticleId></ArticleIdList></Reference><Reference><Citation>J Endourol. 2006 Aug;20(8):586-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16903820</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Oncol Nurs. 2006 Aug;10(4):503-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16927903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sex Med. 2005 Nov;2(6):833-41; discussion 841</Citation><ArticleIdList><ArticleId IdType="pubmed">16422807</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 1999 Dec;11(6):319-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10637462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25208597</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0404</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neurologica Scandinavica</Title><ISOAbbreviation>Acta Neurol Scand</ISOAbbreviation></Journal><ArticleTitle>Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke.</ArticleTitle><Pagination><StartPage>380</StartPage><EndPage>386</EndPage><MedlinePgn>380-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ane.12279</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Tadalafil is a potent and selective phosphodiesterase type 5 inhibitor that provides effective treatment for erectile dysfunction (ED). The purpose of this study was to explore the effect of a single on-demand dose of tadalafil compared to low-dose continuous administration on regional cerebral blood flow (rCBF), in patients after stroke.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty consecutive male patients (mean age 58.3 &#xb1; 7.9 years) with ED and a history of stroke were included in the study. The baseline single-photon emission computed tomography (SPECT) study was performed 15 min after iv injection of 740 MBq Tc-99m-HMPAO (Ceretec; GE Healthcare Ltd. Chalfont St. Giles, UK). Fifteen randomized patients received a single dose of 20 mg tadalafil in the morning, and a second SPECT study was performed 6 h later. Fifteen other patients received 5 mg of tadalafil each morning for seven consecutive days, and the second SPECT study was performed 6 h after the last dose. The imaging data were evaluated using SPM software (Wellcome Department of Cognitive Neurology, University College, London).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Associations between any of the risk factors/comorbidities and the perfusion changes were not detected. All patients showed areas of reduced relative rCBF in the affected hemisphere after tadalafil administration compared to baseline (P &lt; 0.001). No significant difference was found between patients on 5 mg tadalafil and 20 mg dose.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tadalafil administration after cerebral stroke may be associated with diminished blood flow to areas adjacent to the stroke. The alterations in perfusion suggest a need for caution in prescribing tadalafil to patients with a history of stroke, especially with continuous administration that may impose constant stress on the cerebral circulation.</AbstractText><CopyrightInformation>&#xa9; 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lorberboym</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Edith Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makhline</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lampl</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Neurol Scand</MedlineTA><NlmUniqueID>0370336</NlmUniqueID><ISSNLinking>0001-6314</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3B744AG22N</RegistryNumber><NameOfSubstance UI="D019690">Technetium Tc 99m Exametazime</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2015 Apr;193(4):1324-5</RefSource><PMID Version="1">25890543</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019690" MajorTopicYN="N">Technetium Tc 99m Exametazime</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HMPAO</Keyword><Keyword MajorTopicYN="N">SPM</Keyword><Keyword MajorTopicYN="N">Statistical Parametric Mapping</Keyword><Keyword MajorTopicYN="N">cerebral blood flow</Keyword><Keyword MajorTopicYN="N">single-photon emission computed tomography</Keyword><Keyword MajorTopicYN="N">stroke</Keyword><Keyword MajorTopicYN="N">tadalafil</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25208597</ArticleId><ArticleId IdType="doi">10.1111/ane.12279</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25164497</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>16</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Latest pharmacotherapy options for benign prostatic hyperplasia.</ArticleTitle><Pagination><StartPage>2319</StartPage><EndPage>2328</EndPage><MedlinePgn>2319-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656566.2014.955470</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Benign prostatic hyperplasia (BPH) is a very common condition in men over 50 years, often resulting in lower urinary tract symptoms (LUTS). Medical therapy aims at improving quality of life and preventing complications. The range of drugs available to treat LUTS is rapidly expanding.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">Silodosin is a relatively new &#x3b1;1-adrenoreceptor antagonist that is selective for &#x3b1;1A-adrenergic receptor. While causing smooth muscle relaxation in the lower urinary tract, it minimizes blood pressure-related adverse effects. Tadalafil, a PDEs type 5 inhibitor, is a drug recently approved for the treatment of BPH/LUTS that challenges the standard therapy with &#x3b1;1-blockers, especially in men with concomitant erectile dysfunction (ED). Mirabegron is the first &#x3b2;3-adrenoceptor agonist approved for the treatment of symptoms of overactive bladder. BPH-related detrusor overactivity (DO) may be successfully targeted by mirabegron. Gonadotropin-releasing hormone antagonists, intraprostatic injections with NX-1207 and vitamin D3 receptor analogues exerted beneficial effects on LUTS but need further evaluation in clinical studies.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Choosing the right treatment should be guided by patients' symptoms, comorbidities and potential side effects of available drugs. Silodosin is a valid option for elderly and for people taking antihypertensive drugs. BPH patients affected by ED can target both conditions with continuous tadalafil therapy. The encouraging data on mirabegron use in BPH-DO have to be further assessed in larger prospective randomized clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe0; Vita-Salute San Raffaele , Milan , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Croce</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Capogrosso</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ventimiglia</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Colicchia</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Serino</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mirone</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Damiano</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Montorsi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Salonia</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059411" MajorTopicYN="N">Lower Urinary Tract Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">benign prostatic hyperplasia</Keyword><Keyword MajorTopicYN="N">bladder outlet obstruction</Keyword><Keyword MajorTopicYN="N">lower urinary tract symptom</Keyword><Keyword MajorTopicYN="N">medical therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25164497</ArticleId><ArticleId IdType="doi">10.1517/14656566.2014.955470</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25048593</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1576-8260</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Archivos espanoles de urologia</Title><ISOAbbreviation>Arch Esp Urol</ISOAbbreviation></Journal><ArticleTitle>Urethral bleeding after open radical prostatectomy treated with selective arterial embolization. A rare complication.</ArticleTitle><Pagination><StartPage>582</StartPage><EndPage>585</EndPage><MedlinePgn>582-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Gross hematuria in the immediate postoperative radical prostatectomy is a rare complication. According to different series reviewed, significant bleeding after this surgery appears between 0.5-1.5% of the cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">58 year old male with localized prostate cancer who underwent open radical prostatectomy with preservation of the neurovascular bundles and a left accessory pudendal branch. In the 4th postoperative day patient presented severe hematuria and urethral bleeding requiring continuous bladder irrigation and blood transfusion. Given the persistence of bleeding despite conservative measures CT-angiography was performed demonstrating active bleeding at a bulbar artery from the left internal pudendal artery without associated pelvic hematoma</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Given the findings selective embolization was performed with absorbable material stopping the bleeding. Three months later the patient maintains urinary continence and erectile function with tadalafil.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Urethral bleeding after radical prostatectomy is a rare complication the cause of which is distal to the urinary sphincter unrelated to the pelvic vessels. The performance of CT angiography and subsequent embolization is the treatment of choice, avoiding open surgical revision, with less morbidity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molina Escudero</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio Urolog&#xed;a. Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herranz Amo</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Arag&#xf3;n Chamizo</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hernandez Fern&#xe1;ndez</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Arch Esp Urol</MedlineTA><NlmUniqueID>0064757</NlmUniqueID><ISSNLinking>0004-0614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006417" MajorTopicYN="N">Hematuria</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014522" MajorTopicYN="N">Urethral Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25048593</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25018685</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1555-1741</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Core evidence</Title><ISOAbbreviation>Core Evid</ISOAbbreviation></Journal><ArticleTitle>Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.</ArticleTitle><Pagination><StartPage>71</StartPage><EndPage>80</EndPage><MedlinePgn>71-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CE.S50607</ELocationID><Abstract><AbstractText>Pulmonary arterial hypertension (PAH) remains a progressive disease without a cure, despite the development of several treatment options over the past several decades. Its management strategy consists of the endothelin receptor antagonists (ambrisentan, bosentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil), and prostacyclin analogs (epoprostenol, treprostinil, iloprost). Treprostinil, a stable prostacyclin analog, displays vasodilatory effects in the pulmonary vasculature, as well as antiplatelet aggregation properties. Clinical practice guidelines recommend oral endothelin receptor antagonist or phosphodiesterase inhibitor therapy in mild to moderate PAH. Epoprostenol is specifically suggested as first-line therapy in moderate to severe PAH patients (ie, World Health Organization/New York Heart Association functional class III-IV). However, treprostinil may be an alternative option in these severe PAH patients. The longer half-life and stability at room temperature with treprostinil may be associated with lower risk of pulmonary hemodynamic worsening as a result of abrupt infusion discontinuation and less frequent drug preparation. These characteristics make treprostinil an attractive alternative to continuous infusion of epoprostenol, due to convenience and patient safety. The purpose of this review is to evaluate the safety and efficacy of continuous infusion of treprostinil as well as the inhaled and oral routes of administration in PAH.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Mitchell S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Banner Good Samaritan Medical Center, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazem</LastName><ForeName>Nadine H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Shardool A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Banner Estrella Medical Center, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Librodo</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, San Francisco VA Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Core Evid</MedlineTA><NlmUniqueID>101256593</NlmUniqueID><ISSNLinking>1555-1741</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">prostacyclin</Keyword><Keyword MajorTopicYN="N">pulmonary arterial hypertension</Keyword><Keyword MajorTopicYN="N">treprostinil</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25018685</ArticleId><ArticleId IdType="pmc">PMC4073912</ArticleId><ArticleId IdType="doi">10.2147/CE.S50607</ArticleId><ArticleId IdType="pii">ce-9-071</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(Suppl 1):S78&#x2013;S84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686287</ArticleId><ArticleId IdType="pubmed">19555861</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">1863023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">18420094</ArticleId></ArticleIdList></Reference><Reference><Citation>Badesch DB, Champion HC, Gomez-Sanchez MA. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(Suppl 1):S55&#x2013;S66.</Citation><ArticleIdList><ArticleId IdType="pubmed">19555859</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">6148159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D42&#x2013;D50.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355641</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D34&#x2013;D41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355639</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389575</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(Suppl 12):13S&#x2013;24S.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194174</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">1603138</ArticleId></ArticleIdList></Reference><Reference><Citation>Steudel W, Ichinose F, Huang PL, et al. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res. 1997;81(1):34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">9201025</ArticleId></ArticleIdList></Reference><Reference><Citation>Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">12204511</ArticleId></ArticleIdList></Reference><Reference><Citation>Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J. 2009;30(20):2493&#x2013;2537.</Citation><ArticleIdList><ArticleId IdType="pubmed">19713419</ArticleId></ArticleIdList></Reference><Reference><Citation>Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(Suppl D):D60&#x2013;D72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355643</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonneau G, Barst RJ, Galie N, et al. Continuous SubQ infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897647</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129(3):683&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">16537868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with IV treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">20022264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang I, Gomez-Sanchez M, Kneussl, et al. Efficacy of long-term SubQ treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129(6):1636&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16778286</ArticleId></ArticleIdList></Reference><Reference><Citation>Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with SubQ treprostinil. Eur Respir J. 2006;28(6):1195&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899485</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study) Chest. 2012;142(6):1383&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">22628490</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension. Circulation. 2013;127(5):624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">23307827</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study) Chest. 2013;144(3):952&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">23669822</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2010;55(18):1915&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pubmed">20430262</ArticleId></ArticleIdList></Reference><Reference><Citation>Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the treprostinil sodium inhalation used in the management of pulmonary arterial hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011;30(12):1327&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">22055098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005;96(9):1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pubmed">16253609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz M, Escribano P, Delgado J, et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J Heart Lung Transplant. 2006;25(11):1353&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097500</ArticleId></ArticleIdList></Reference><Reference><Citation>Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest. 2008;134(1):139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudaca G, Spano F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf. 2014;13(3):295&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">24387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Vachiery JL, Naeije R. Treprostinil for pulmonary hypertension. Expert Rev Cardiovasc Ther. 2004;2(2):183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15151467</ArticleId></ArticleIdList></Reference><Reference><Citation>Remodulin&#xae; (treprostinil) [package insert] Research Triangle Park, NC: United Therapeutics Corporation; 2013.</Citation></Reference><Reference><Citation>Orenitram&#x2122; (treprostinil) extended-release tablets for oral administration [package insert] Research Triangle Park, NC: United Therapeutics Corporation; 2013.</Citation></Reference><Reference><Citation>Tyvaso&#xae; (treprostinil) inhalation solution [package insert] Research Triangle Park, NC: United Therapeutics Corporation; 2013.</Citation></Reference><Reference><Citation>Wade M, Hunt TL, Lai AA. Effect of continuous SubQ treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol. 2003;41(6):908&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">12775969</ArticleId></ArticleIdList></Reference><Reference><Citation>McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol. 2008;48(1):19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094217</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013;11(1):13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">23259441</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(3):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548091</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24180640</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-960X</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of chemical information and modeling</Title><ISOAbbreviation>J Chem Inf Model</ISOAbbreviation></Journal><ArticleTitle>The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.</ArticleTitle><Pagination><StartPage>3044</StartPage><EndPage>3053</EndPage><MedlinePgn>3044-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/ci400458z</ELocationID><Abstract><AbstractText>Great attention has been paid to the clinical significance of phosphodiesterase 5 (PDE5) inhibitors, such as sildenafil, tadalafil, and vardenafil widely used for erectile dysfunction. However, sildenafil causes side effects on visual functions since it shows similar potencies to inhibit PDE5 and PDE6, whereas tadalafil gives a high selectivity of 1020-fold against PDE6. Till now, their molecular mechanisms of selectivity of PDE5 versus PDE6 have remained unknown in the absence of the crystal structure of PDE6. In order to elucidate its isoform-selective inhibitory mechanism, a 3D model of PDE6 was constructed by homology modeling, and its interaction patterns with tadalafil plus sildenafil were exploited by molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations. The present work reveals that tadalafil exhibits a less negative predicted binding free energy of -35.21 kcal/mol with PDE6 compared with the value of -41.12 kcal/mol for PDE5, which suggests that tadalafil prefers PDE5 rather than PDE6 and confers a high selectivity for PDE5 versus PDE6. The binding free energy results for tadalafil were consistent with external bioassay studies (IC50 = 5100 and 5 nM toward PDE6 and PDE5, respectively). Two important residues from the Q2 pockets (Val782 and Leu804 in PDE5 and their corresponding Val738 and Met760 in PDE6) were further identified to account for the high selectivity of tadalafil for PDE5 versus PDE6. These findings have shed light on the continuous puzzle of why sildenafil (IC50 = 74 and 6 nM toward PDE6 and PDE5, respectively) causes visual disorders because of its poor selectivity but tadalafil does not. In addition, the homology model of PDE6 can be used to design more potent and selective second-generation PDE5 inhibitors with less inhibitory potency against PDE6.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yi-You</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Sun Yat-Sen University , Guangzhou 510006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Ying-Hong</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Ling-Jun</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yinuo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xingshu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Hai-Bin</ForeName><Initials>HB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Chem Inf Model</MedlineTA><NlmUniqueID>101230060</NlmUniqueID><ISSNLinking>1549-9596</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064804">Urological Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054707">Cyclic Nucleotide Phosphodiesterases, Type 6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054707" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040681" MajorTopicYN="N">Structural Homology, Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064804" MajorTopicYN="N">Urological Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24180640</ArticleId><ArticleId IdType="doi">10.1021/ci400458z</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">23845082</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-6109</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Community pharmacy detection of erectile dysfunction in men with risk factors or who seek treatment or advice but lack a valid prescription.</ArticleTitle><Pagination><StartPage>2303</StartPage><EndPage>2311</EndPage><MedlinePgn>2303-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jsm.12238</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Pharmacists may be the first health care contact consulted about erectile dysfunction (ED).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess pharmacists' ability to detect ED and encourage patients to seek medical evaluation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This observational study conducted in Greece and Spain included men without a valid prescription for an ED medication but with a history indicating ED risk and/or who consulted a pharmacist about ED. Pharmacists completed a questionnaire about the patient. Patients completed the Sexual Health Inventory for Men (SHIM); men with a score &#x2264;21 (cutoff for ED) were educated (by case pharmacists) and referred and encouraged to see a physician (by case and control pharmacists).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Proportion of men with a SHIM score &#x2264;21 and, of those, the proportion who visited a physician and credited the pharmacist for their visit. ANCOVA and chi-square test were used for continuous and categorical data, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 451 men (mean&#x2009;&#xb1;&#x2009;SD age, 54.9&#x2009;&#xb1;&#x2009;12.9&#x2009;years) questioned about ED, 90% had a risk factor (usually hypertension, hypercholesterolemia, or diabetes), 28% had a previous diagnosis, 36% sought internet information, 38% self-medicated, 10% took medication obtained outside the pharmacy setting, and the first health care professional approached was a pharmacist (50%), physician (18%), or nurse (1%) at a median of 6 (range, 0-360) months after symptom onset. The SHIM score was &#x2264;21 in 348 (77%) men. A lower score (indicating increased ED severity) was associated with increased age and with benign prostate hyperplasia, depression, diabetes, or prostate cancer. In the minority of men contacted for follow-up, less than one-third had visited their physician, despite pharmacist encouragement.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pharmacists are often the first health care contact regarding ED and are highly accurate in its detection. Further research is needed to optimize the pharmacist's role in early detection, education, and motivating patients to be evaluated by a physician.</AbstractText><CopyrightInformation>&#xa9; 2013 International Society for Sexual Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin Morales</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Carlos Haya University Hospital, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatzichristou</LastName><ForeName>Dimitris</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ramon Llad&#xf3;s</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pascual Renedo</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Pimenidou</LastName><ForeName>Apostolia</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003157" MajorTopicYN="Y">Community Pharmacy Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006115" MajorTopicYN="N">Greece</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010595" MajorTopicYN="Y">Pharmacists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024382" MajorTopicYN="N">Professional Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="N">Professional-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Community Pharmacy Services</Keyword><Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword><Keyword MajorTopicYN="N">Patient Education Handout</Keyword><Keyword MajorTopicYN="N">Patient Education as Topic</Keyword><Keyword MajorTopicYN="N">Phosphodiesterase Inhibitors</Keyword><Keyword MajorTopicYN="N">Prescription</Keyword><Keyword MajorTopicYN="N">Referral and Consultation</Keyword><Keyword MajorTopicYN="N">Sildenafil</Keyword><Keyword MajorTopicYN="N">Tadalafil</Keyword><Keyword MajorTopicYN="N">Vardenafil</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23845082</ArticleId><ArticleId IdType="doi">10.1111/jsm.12238</ArticleId><ArticleId IdType="pii">S1743-6095(15)30486-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23266759</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3476</ISSN><JournalIssue CitedMedium="Internet"><Volume>441</Volume><Issue>1-2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Drug-printing by flexographic printing technology--a new manufacturing process for orodispersible films.</ArticleTitle><Pagination><StartPage>818</StartPage><EndPage>825</EndPage><MedlinePgn>818-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2012.12.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-5173(12)01086-1</ELocationID><Abstract><AbstractText>Orodispersible films (ODFs) are intended to disintegrate within seconds when placed onto the tongue. The common way of manufacturing is the solvent casting method. Flexographic printing on drug-free ODFs is introduced as a highly flexible and cost-effective alternative manufacturing method in this study. Rasagiline mesylate and tadalafil were used as model drugs. Printing of rasagiline solutions and tadalafil suspensions was feasible. Up to four printing cycles were performed. The possibility to employ several printing cycles enables a continuous, highly flexible manufacturing process, for example for individualised medicine. The obtained ODFs were characterised regarding their mechanical properties, their disintegration time, API crystallinity and homogeneity. Rasagiline mesylate did not recrystallise after the printing process. Relevant film properties were not affected by printing. Results were comparable to the results of ODFs manufactured with the common solvent casting technique, but the APIs are less stressed through mixing, solvent evaporation and heat. Further, loss of material due to cutting jumbo and daughter rolls can be reduced. Therefore, a versatile new manufacturing technology particularly for processing high-potent low-dose or heat sensitive drugs is introduced in this study.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Eva Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, Universit&#xe4;tsstr. 1, 40225 D&#xfc;sseldorf, Germany. e.m.hoffmann@uni-duesseldorf.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schliephacke</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Breitenbach</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Breitkreutz</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012997">Solvents</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012997" MajorTopicYN="N">Solvents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23266759</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2012.12.023</ArticleId><ArticleId IdType="pii">S0378-5173(12)01086-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22297243</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.</ArticleTitle><Pagination><StartPage>917</StartPage><EndPage>925</EndPage><MedlinePgn>917-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2012.01.013</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH; LUTS/BPH) in clinical studies but has not been evaluated together with an active control in an international clinical study.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Assess tadalafil or tamsulosin versus placebo for LUTS/BPH.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A randomised, double-blind, international, placebo-controlled, parallel-group study assessed men &#x2265;45 yr of age with LUTS/BPH, International Prostate Symptom Score (IPSS) &#x2265;13, and maximum urinary flow rate (Q(max)) &#x2265;4 to &#x2264;15ml/s. Following screening and washout, if needed, subjects completed a 4-wk placebo run-in before randomisation to placebo (n=172), tadalafil 5mg (n=171), or tamsulosin 0.4mg (n=168) once daily for 12 wk.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Outcomes were assessed using analysis of covariance (ANCOVA) or ranked analysis of variance (ANOVA) (continuous variables) and Cochran-Mantel-Haenszel test or Fisher exact test (categorical variables).</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">IPSS significantly improved versus placebo through 12 wk with tadalafil (-2.1; p=0.001; primary efficacy outcome) and tamsulosin (-1.5; p=0.023) and as early as 1 wk (tadalafil and tamsulosin both -1.5; p&lt;0.01). BPH Impact Index significantly improved versus placebo at first assessment (week 4) with tadalafil (-0.8; p&lt;0.001) and tamsulosin (-0.9; p&lt;0.001) and through 12 wk (tadalafil -0.8, p=0.003; tamsulosin -0.6, p=0.026). The IPSS Quality-of-Life Index and the Treatment Satisfaction Scale-BPH improved significantly versus placebo with tadalafil (both p&lt;0.05) but not with tamsulosin (both p&gt;0.1). The International Index of Erectile Function-Erectile Function domain improved versus placebo with tadalafil (4.0; p&lt;0.001) but not tamsulosin (-0.4; p=0.699). Q(max) increased significantly versus placebo with both tadalafil (2.4ml/s; p=0.009) and tamsulosin (2.2ml/s; p=0.014). Adverse event profiles were consistent with previous reports. This study was limited in not being powered to directly compare tadalafil versus tamsulosin.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Monotherapy with tadalafil or tamsulosin resulted in significant and numerically similar improvements versus placebo in LUTS/BPH and Q(max). However, only tadalafil improved erectile dysfunction.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov ID NCT00970632.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oelke</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Urology, Hannover Medical School, Hannover, Germany. oelke.matthias@mh-hannover.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuliano</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mirone</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Viktrup</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00970632</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058668">Adrenergic alpha-1 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>G3P28OML5I</RegistryNumber><NameOfSubstance UI="D000077409">Tamsulosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2012 May;61(5):926-7</RefSource><PMID Version="1">22397848</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2012 Aug;62(2):e39; author reply e40</RefSource><PMID Version="1">22633359</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2012 Sep;62(3):e63-4</RefSource><PMID Version="1">22709717</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2012 Sep;188(3):904-5</RefSource><PMID Version="1">22883791</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2013 Apr;189(4):1448-9</RefSource><PMID Version="1">23561361</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D058668" MajorTopicYN="N">Adrenergic alpha-1 Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059411" MajorTopicYN="N">Lower Urinary Tract Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077409" MajorTopicYN="N">Tamsulosin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22297243</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2012.01.013</ArticleId><ArticleId IdType="pii">S0302-2838(12)00015-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21871706</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>1105</StartPage><EndPage>1113</EndPage><MedlinePgn>1105-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2011.08.005</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH-LUTS).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess efficacy, including onset, and safety of tadalafil on BPH-LUTS and the subject's and clinician's perception of changes in urinary symptoms.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This randomized, double-blind, placebo-controlled, 12-week trial enrolled men &#x2265;45 yr of age with BPH-LUTS for &gt;6 mo, International Prostate Symptom Score (IPSS) &#x2265;13, and maximum urine flow rate (Q(max)) &#x2265;4 to &#x2264;15 ml/s.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Tadalafil 5mg (n=161) or placebo (n=164), once daily.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Analysis of covariance (ANCOVA) modeling evaluated change from baseline in continuous efficacy variables. Categoric efficacy variables were analyzed with the Cochran-Mantel-Haenszel test, and between-group differences in treatment-emergent adverse events (TEAEs) were assessed using the Fisher exact test. RESULTS AND LIMITATION: Tadalafil significantly improved IPSS results, from baseline to endpoint, compared to placebo (-5.6 vs -3.6; p=0.004). Reduction in IPSS results was apparent after 1 wk and significant after 4 wk (tadalafil -5.3 vs placebo -3.5; p=0.003). The BPH Impact Index (BII) was not assessed at week 1; however, BII improvement was apparent at 4 wk (tadalafil -1.8 vs placebo -1.2; p=0.029) and continued at 12 wk (tadalafil -1.8 vs placebo -1.3; p=0.057). Tadalafil significantly improved the International Index of Erectile Function-Erectile Function score in sexually active men with erectile dysfunction (ED; 6.7 vs 2.0; p&lt;0.001) at 12 wk (not assessed at week 1). Few subjects reported one TEAE or more (p=0.44). For tadalafil, the most common TEAEs were headache (3.7%) and back pain (3.1%). Tadalafil did not significantly improve Q(max) or reduce postvoid residual volume.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tadalafil 5mg once daily for 12 wk resulted in a clinically meaningful reduction in total IPSS results as early as 1 wk and achieved statistical significance at 4 wk in men with BPH-LUTS. The adverse event profile was consistent with that previously reported in men with ED.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This clinical trial is registered on the clinicaltrials.gov website (http://www.clinicaltrials.gov). The registration number is NCT00827242.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Porst</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>porst20354@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Casab&#xe9;</LastName><ForeName>Adolfo R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Mirone</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Secrest</LastName><ForeName>Roberta J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sundin</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Viktrup</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><CollectiveName>LVHJ study team</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00827242</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Urol. 2011 Dec;8(12):643</RefSource><PMID Version="1">22083242</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2012 Mar;187(3):990</RefSource><PMID Version="1">22325528</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2012 May;61(5):e45-6; author reply e47-8</RefSource><PMID Version="1">22342774</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059411" MajorTopicYN="N">Lower Urinary Tract Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="N">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014554" MajorTopicYN="N">Urination</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014563" MajorTopicYN="N">Urodynamics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Casab&#xe9;</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bl&#xf6;mers</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helder</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porst</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quast</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Keitz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canclini</LastName><ForeName>L P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gentile</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirone</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montorsi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpa</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrios</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marinez-Montelongo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rueda</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zepeda</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aliotta</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccia</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donatucci</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eure</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambla</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaminetsky</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kriteman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMurray</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McVary</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21871706</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2011.08.005</ArticleId><ArticleId IdType="pii">S0302-2838(11)00865-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19957535</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0376-2491</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>24</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Zhonghua yi xue za zhi</Title><ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Effect of tadalafil therapy upon penile cavernous tissues in spontaneously hypertensive rats].</ArticleTitle><Pagination><StartPage>1717</StartPage><EndPage>1720</EndPage><MedlinePgn>1717-20</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">OBJECTIVE; To observe the plasma concentration change of endothelin-1 (ET-1) and the histomorphological changes in penile cavernous body after administrating a continuous low dose of tadalafil into spontaneously hypertensive rats (SHR).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty SHR rats were randomly divided into four groups of blank group, placebo group, continuous low-dose group and intermittent dose group with 10 rats in each. The animals were administrated with different doses of tadalafil via an intragastric route. To observe the plasma concentration change of ET-1 and cellular morphological changes of penile cavernous tissue in SHR after four weeks, the immunohistochemical method of SABC was employed to detect the expression of alpha-smooth muscle actin (alpha-SMA) in penile corpora cavernous of different groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The plasma levels of ET-1 were lower in continuous low dose group (12.0 +/- 1.6) and intermittent dose group (14.3 +/- 1.7) as compared with the blank (18.0 +/- 1.9) and placebo groups (17.6 +/- 2.2) (all P &lt; 0.01). And there was significant difference between the continuous low dose and intermittent dose groups (P &lt; 0.05). The A-value level of absorbance in alpha-SMA were significantly different with the blank (0.53 +/- 0.03) and placebo groups (0.52 +/- 0.05) (P &gt; 0.05) and it was lower in the continuous low dose group (0.29 +/- 0.03) than the intermittent dose group (0.38 +/- 0.03) (P &lt; 0.05). It can be observed microscopically that in blank group and placebo group: endothelial cell and vascular smooth muscle cells of penile cavernous tissue in SHR had a disorderly distribution. The disrupted continuity and integrity of endothelial cell were also found. And they improved in continuous low dose group and intermittent dose group, especially the former; it can be viewed under TEM that the endothelial cells of penile cavernous tissue in SHR had mostly reverted to normal condition in the continuous low dose group and its ultra-structure indicated that the tissue morphology improved.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A continuous low dose of tadalafil can improve the function and structure of vascular endothelium in penile cavernous body. Thus it provides rationales for a continuous low dose of PDE5 inhibitor in the treatment of erectile dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhi-Gang</ForeName><Initials>ZG</Initials><AffiliationInfo><Affiliation>Department of Urology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wen-Lan</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiu-Ling</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang-Bin</ForeName><Initials>XB</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Cheng-Di</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Zhi-Liang</ForeName><Initials>ZL</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7511141</NlmUniqueID><ISSNLinking>0376-2491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019332">Endothelin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019332" MajorTopicYN="N">Endothelin-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011918" MajorTopicYN="N">Rats, Inbred SHR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19957535</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">18984932</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0019-4832</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Indian heart journal</Title><ISOAbbreviation>Indian Heart J</ISOAbbreviation></Journal><ArticleTitle>Tadalafil in the management of severe pulmonary artery hypertension.</ArticleTitle><Pagination><StartPage>52</StartPage><EndPage>53</EndPage><MedlinePgn>52-3</MedlinePgn></Pagination><Abstract><AbstractText>Severe oyknibart arterial hypertension is a life-threatening disease with a poor prognosis. Continuous intravenous infusion of prostacyclin has proved effective in this condition. However, it carries the risk of serious complications arising from the complex delivery system along with a high cost. Prostacyclin analogs, endothelin antagonists, and the phophodiesterase-5 inhibitor sildenafil are emerging and promisinge therapies. Tadalafil, like sildenafil, is a selective phosphodiesterase-5 inhibitor with a longer duration of action. We repport the use of tadalafil in two patients of severe pulmonary arterial hypertension who could not afford expensive treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Thokchom Sd</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Medicine and Cardiology, Regional Institute of Medical Sciences, Imphal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Dilip</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Soumik</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Panja</LastName><ForeName>Manotosh</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mitra</LastName><ForeName>Bishwanath</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian Heart J</MedlineTA><NlmUniqueID>0374675</NlmUniqueID><ISSNLinking>0019-4832</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18984932</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18290855</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1464-5491</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Diabetic medicine : a journal of the British Diabetic Association</Title><ISOAbbreviation>Diabet Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>146</EndPage><MedlinePgn>138-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1464-5491.2007.02338.x</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Erectile dysfunction (ED) is a common comorbidity in men with diabetes mellitus. Tadalafil 10 or 20 mg taken on demand is efficacious and safe for men with diabetes and ED. Recently, continuous treatment with tadalafil has been proposed, addressing ED management as any other chronic condition. This study examined whether once-daily tadalafil 2.5 and 5 mg is efficacious for men with diabetes and ED.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, double-blind, placebo-controlled, multicentre, 12-week study enrolled 298 men with diabetes and ED to once-daily treatment with placebo, tadalafil 2.5 mg or tadalafil 5 mg. Primary efficacy measures were International Index of Erectile Function Erectile Function (IIEF EF) Domain score, and patient success rates for vaginal penetration and completion of intercourse. Patient satisfaction, endothelial function biomarkers, and safety were also assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients receiving either dose of tadalafil had clinically and statistically significant improvements in IIEF EF and statistically significant improvements in mean success rates for vaginal penetration, completion of intercourse, and overall treatment satisfaction (P &lt; or = 0.005 tadalafil vs. placebo, all measures). Endothelial dysfunction biomarkers were unchanged. The most common adverse events were headache, back pain and dyspepsia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this first study of men with diabetes and ED, once-daily tadalafil 2.5 and 5 mg was efficacious and well tolerated, suggesting this may be an alternative to on-demand treatment for some men, eliminating the need to plan sex within a limited timeframe.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hatzichristou</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aristotle University of Thessaloniki, Department of Urology, Thessaloniki, Greece. hatzichr@med.auth.gr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambla</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rubio-Aurioles</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Buvat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>G B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Spera</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lording</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabet Med</MedlineTA><NlmUniqueID>8500858</NlmUniqueID><ISSNLinking>0742-3071</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003075" MajorTopicYN="N">Coitus</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18290855</ArticleId><ArticleId IdType="doi">10.1111/j.1464-5491.2007.02338.x</ArticleId><ArticleId IdType="pii">DME2338</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17888043</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-410X</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int</ISOAbbreviation></Journal><ArticleTitle>Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection.</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>210</EndPage><MedlinePgn>203-10</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether a long-term single daily oral dose of a longer half-life phosphodiesterase-5 (PDE5) inhibitor, tadalafil, has a similar effect to that of the shorter half-life PDE5 inhibitors sildenafil and vardenafil, and can prevent the fibrosis and resultant corporal veno-occlusive dysfunction (CVOD) occurring after cavernosal nerve (CN) injury.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Male rats (10 per group) had either a sham operation, unilateral CN resection (CNR) or bilateral CNR, and were left untreated or given retrolingually 5 mg/kg per day of tadalafil. After 45 days, CVOD was assessed via cavernosometry, and the underlying corporal tissue changes were examined by immunohistochemistry and histochemistry (followed by quantitative image analysis), Western blots, and ad hoc methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tadalafil treatment normalized the low response to papaverine and high drop rate in the intracavernosal pressure measured by cavernosometry after CNR compared with sham-operated rats. Tadalafil also normalized the increase in penile shaft collagen content, and the reduction in corporal smooth muscle cell (SMC) content, SMC/collagen, and replication index, and improved the lower collagen III/I ratio and the increase in apoptotic index, caused by CNR, compared with sham operation. There were no effects of tadalafil on increased transforming growth factor beta1, inducible nitric oxide synthase and xanthine oxidoreductase levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A long-term single daily dose of tadalafil prevented CVOD and the underlying corporal fibrosis in the rat caused by CN damage, as effectively as the previously reported continuous treatment with vardenafil or sildenafil, through a cGMP-related mechanism that appears to be independent of inducible nitric oxide synthase induction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kovanecz</LastName><ForeName>Istvan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Urology Research Laboratory, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rambhatla</LastName><ForeName>Amarnath</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ferrini</LastName><ForeName>Monica G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Vernet</LastName><ForeName>Dolores</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rajfer</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez-Cadavid</LastName><ForeName>Nestor</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5P20MD000545</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G12RR-03026</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK-53069</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003714" MajorTopicYN="N">Denervation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018783" MajorTopicYN="N">Impotence, Vasculogenic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="Y">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17888043</ArticleId><ArticleId IdType="doi">10.1111/j.1464-410X.2007.07223.x</ArticleId><ArticleId IdType="pii">BJU7223</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17623085</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1752-1947</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><PubDate><Year>2007</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report.</ArticleTitle><Pagination><StartPage>46</StartPage><MedlinePgn>46</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Portopulmonary hypertension (PPHTN) is a severe complication in liver cirrhosis. PDE5 inhibitors lower pulmonary arterial pressure (PAP) in PPHTN. However, their effect on portal hypertension has not yet been investigated.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 55 year old male patient presented with PPHTN and alcoholic liver cirrhosis. 10 mg of Tadalafil, a PDE5 inhibitor with a long half-life, was administered orally under continuous monitoring of pulmonary and portal hemodynamics. For maintenance therapy the patient received Sildenafil 20 mg bid.Tadalafil lowered mean PAP from 45 to 39 mmHg within 60 minutes. Cardiac output (CO) increased from 6.8 to 7.9 l/min. Central venous pressure (CVP) remained stable at 3 mmHg. Systolic and diastolic blood pressure was lowered from 167/89 to 159/86 mmHg. Pulse rate increased from 75 to 87 per min. Wedged hepatic vein pressure (WHVP) decreased from 21 to 18 mm Hg, hepatovenous pressure gradient (HVPG) decreased from 10 to 7 mmHg. Hemodynamic monitoring after 6 months of Sildenafil therapy revealed a sustained lowering of mean PAP. HVPG remained constant at 10 mmHg. Cardiac and pulmonary performance had further improved.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case report shows for the first time, that phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bremer</LastName><ForeName>Hinrich C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University Hospital, Freiburg, Germany. wolfgang.kreisel@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreisel</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Roecker</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dreher</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Koenig</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kurz-Schmieg</LastName><ForeName>Anna Katharina</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Hubert E</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>Roessle</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Deibert</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17623085</ArticleId><ArticleId IdType="pmc">PMC1971060</ArticleId><ArticleId IdType="doi">10.1186/1752-1947-1-46</ArticleId><ArticleId IdType="pii">1752-1947-1-46</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004;126:903&#x2013;913. doi: 10.1053/j.gastro.2003.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2003.11.046</ArticleId><ArticleId IdType="pubmed">14988844</ArticleId></ArticleIdList></Reference><Reference><Citation>Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology. 2006;44:1502&#x2013;1510. doi: 10.1002/hep.21431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.21431</ArticleId><ArticleId IdType="pubmed">17133488</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120&#x2013;126. doi: 10.1053/j.gastro.2005.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.10.013</ArticleId><ArticleId IdType="pubmed">16401475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689&#x2013;702. doi: 10.1038/nrd2030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2030</ArticleId><ArticleId IdType="pmc">PMC7097805</ArticleId><ArticleId IdType="pubmed">16883306</ArticleId></ArticleIdList></Reference><Reference><Citation>Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, R&#xf6;ssle M, Kreisel W. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. Aliment Pharmacol Ther. 2006;23:121&#x2013;128. doi: 10.1111/j.1365-2036.2006.02735.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2006.02735.x</ArticleId><ArticleId IdType="pubmed">16393289</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, Seeger W, Ghofrani HA. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28:563&#x2013;567. doi: 10.1183/09031936.06.00030206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.06.00030206</ArticleId><ArticleId IdType="pubmed">16807265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YW, Lin HC, Yang YY, Hou MC, Lee SD. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol. 2006;41:593&#x2013;597. doi: 10.1007/s00535-006-1809-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-006-1809-y</ArticleId><ArticleId IdType="pubmed">16868809</ArticleId></ArticleIdList></Reference><Reference><Citation>Finley DS, Lugo B, Ridgway J, Teng W, Imagawa DK. Fatal variceal rupture after sildenafil use: report of a case. Curr Surg. 2005;62:55&#x2013;56. doi: 10.1016/j.cursur.2004.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cursur.2004.06.019</ArticleId><ArticleId IdType="pubmed">15708146</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzathas C, Christidou A, Ladas SD. Sildenafil (viagra) is a risk factor for acute variceal bleeding. Am J Gastroenterol. 2002;97:1856. doi: 10.1111/j.1572-0241.2002.05876.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2002.05876.x</ArticleId><ArticleId IdType="pubmed">12135063</ArticleId></ArticleIdList></Reference><Reference><Citation>Colle I, De Vriese AS, Van Vlierberghe H, Lameire NH, DeVos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int. 2004;24:63&#x2013;68. doi: 10.1111/j.1478-3231.2004.00892.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2004.00892.x</ArticleId><ArticleId IdType="pubmed">15102002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17213792</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0391-1977</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Minerva endocrinologica</Title><ISOAbbreviation>Minerva Endocrinol</ISOAbbreviation></Journal><ArticleTitle>Tadalafil and modifications in peak systolic velocity (Doppler spectrum dynamic analysis) in the cavernosal arteries of patients with type 2 diabetes after continuous tadalafil treatment.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>261</EndPage><MedlinePgn>251-61</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">In this study peak systolic velocity (PSV) was measured by penile duplex Doppler spectrum dynamic analysis in diabetic patients with erectile dysfunction (ED) administered continuous treatment with tadalafil for 3 months in a weekly regimen (Monday-Wednesday-Friday). Responses to the Structured Interview on Erectile Dysfunction (SIEDY) questionnaire and hormonal blood levels (LH, testosterone, prolactin) were studied before and after treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study sample was 20 diabetic patients (mean age 60 years; range 55-65) with organic vascular arterial ED at enrollment into the study. All patients were eligible for receiving tadalafil. Patients were randomly assigned to 2 different treatment groups according to a computer-generated list. The first random set of numbers was assigned to group A, the second to group B. Group A (n=10) received tadalafil 20 mg per os on demand for 3 months (Cialis, Lilly ICOS; London, UK). Group B (n=10) received tadalafil 20 mg per os on weekly fixed days (Monday-Wednesday-Friday) for 3 months. All patients underwent duplex penile sonographic dynamic evaluation after intracavernosal injection of alprostadil 20 microg (Caverject, Pharmacia SpA; Milan, Italy); SIEDY questionnaire responses and changes in blood hormonal levels (LH, testosterone, prolactin) before and after treatment were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Increased PSV at 10 min and 20 min after alprostadil administration was found in 30% of Group A patients and in 60% of Group B patients. In 40% of Group B patients, the increase in PSV was so significant as to justify reclassification to a less severe diagnostic category (Benson classification) in vascular profile. No changes in hormonal levels after treatment were found in either group. Analysis of the questionnaires showed a more marked reduction in the global total scores in Group B, with a greater frequency and a clearer improvement in global scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study on a group of 20 patients with organic vascular arterial ED disclosed at least 2 basic aspects: 1) a higher percentage of Group B patients (fixed-day treatment regimen) showed a greater improvement in PSV than the controls; 40% of these patients were reclassified according to the Benson classification; 2) within the context of a clinical study, monitoring and supportive care to increase the frequency and quality of sexual intercourse led to a resumption of and a greater interest in sexual activity. This finding cannot be explained by changes in hormonal levels; instead, there appeared a sort of effect placebo that the continuous therapy, like conventional treatment for other health reasons, had on the patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>La Vignera</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Endocrinology, Andrology and Internal Medicine, Department of Biomedical Sciences, Garibaldi Hospital, University of Catania, Catania, Italy. sandrolavignera@email.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calogero</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Cannizzaro</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Condorelli</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Noto</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Vicari</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><Language>ita</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Endocrinol</MedlineTA><NlmUniqueID>8406505</NlmUniqueID><ISSNLinking>0391-1977</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-62-4</RegistryNumber><NameOfSubstance UI="D011388">Prolactin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-67-9</RegistryNumber><NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>F5TD010360</RegistryNumber><NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000527" MajorTopicYN="N">Alprostadil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001158" MajorTopicYN="N">Arteries</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003925" MajorTopicYN="N">Diabetic Angiopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010413" MajorTopicYN="N">Penis</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17213792</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17100941</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1743-6095</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The journal of sexual medicine</Title><ISOAbbreviation>J Sex Med</ISOAbbreviation></Journal><ArticleTitle>Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.</ArticleTitle><Pagination><StartPage>1077</StartPage><EndPage>1084</EndPage><MedlinePgn>1077-1084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-6109.2006.00333.x</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-6095(15)31410-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Recurrent ischemic priapism is an enigmatic erectile disorder in need of improved clinical interventions to avert its known, potentially serious complications.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the use of a long-term, continuous phosphodiesterase type 5 (PDE5) inhibitor therapeutic regimen in controlling recurrent ischemic priapism and its feasibility in a clinical management program for the disorder.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The main outcome measure was reduction in frequency or duration of priapism episodes. A secondary outcome measure was preservation of erectile ability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively evaluated the clinical progress of seven patients (age 22-37 years) with sickle cell disease-associated "stuttering" priapism (N = 4) and idiopathic recurrent priapism (N = 3), who were counseled and consented to the "off-label" use of the PDE5 inhibitors sildenafil citrate and tadalafil. The medications were administered according to a specified therapeutic regimen based on scientific evidence that chronic PDE5 inhibitor administration in priapism contexts effectively reconditions PDE5 regulatory function in the penis. The duration of clinical follow-up extended through 2 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All seven patients were confirmed to have recurrent ischemic priapism without identifiable pharmacologic, traumatic, or neoplastic disease associations based on clinical history, physical examination, laboratory testing, and penile diagnostics. PDE5 inhibitor treatment was successful in alleviating or resolving priapism recurrences in six of the seven patients. Erectile function was unchanged in six patients and improved in one patient at last follow-up compared with baseline status. All the patients reported that PDE5 inhibitor therapy was well tolerated and did not cause any adverse effects limiting their continued use of the medication.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Because of their efficacy, safety, and tolerability as shown in this case series, PDE5 inhibitors would appear to have a possible role in a rigorously implemented clinical management program to control recurrent priapism. However, completion of a controlled clinical trial is necessary to confirm the utility of this treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Arthur L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Johns Hopkins University-Urology, Baltimore,. Electronic address: aburnett@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bivalacqua</LastName><ForeName>Trinity J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Johns Hopkins University-Urology, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Champion</LastName><ForeName>Hunter C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Johns Hopkins University-Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musicki</LastName><ForeName>Biljana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Johns Hopkins University-Urology, Baltimore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Sex Med</MedlineTA><NlmUniqueID>101230693</NlmUniqueID><ISSNLinking>1743-6095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="C517381">PDE5A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2007 Sep;52(3):918-9</RefSource><PMID Version="1">17855853</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010410" MajorTopicYN="N">Penile Erection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011317" MajorTopicYN="N">Priapism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17100941</ArticleId><ArticleId IdType="doi">10.1111/j.1743-6109.2006.00333.x</ArticleId><ArticleId IdType="pii">S1743-6095(15)31410-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16564127</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0302-2838</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>133</EndPage><MedlinePgn>126-32; discussion 132-3</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To develop and test step-wise treatment strategy for erectile dysfunction "non-responders" to tadalafil and vardenafil.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Two groups [tadalafil-treated (TG); vardenafil-treated (VG)] of 100 consecutive patients complaining of non-response to treatments were enrolled in three-phase study. Phase 1: inadequate use was identified and patients were rechallenged, after receiving detailed usage information. Phase 2: true non-responders were given new instructions based on drugs' pharmacologic profiles: TGs were dosed at least 2 h before intercourse; VGs were dosed only in fasted state. Remaining non-responders entered phase 3: continuous administration of 20 mg tadalafil every other day, or 20 mg vardenafil every day for 2 weeks. Efficacy was based on positive (yes) response to two questions: "Were your erections rigid, and did they last long enough to have successful intercourse?" and "Do you want to repeat your prescription?"</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tadalafil group: Inappropriate use was recognized in 32 patients; 14 (43.75%) responded after adequate instruction. Phase 2: 32 of 86 (37.2%) had intercourse at least 2 h after dose intake. Phase 3: 6 of 86 (11.1%) responded to continuous administration. Overall salvage rate was 52 of 100 (52%). Vardenafil group: Inappropriate use was recognized in 38 patients; 12 (31.58%) responded after adequate instruction. Phase 2, 22 of 88 (25%) responded to dosing in a fasted state. Phase 3: 12 of 66 (18.2%) responded to daily dosing. Overall salvage rate was 46 of 100 (46%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Following proposed treatment strategy may maximize response rate to phosphodiesterase 5 inhibitors; appropriate usage instructions may play significant role in response rate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hatzimouratidis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The 2nd Department of Urology, Papageorgiou General Hospital, and the Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moysidis</LastName><ForeName>Kyriakos</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bekos</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tsimtsiou</LastName><ForeName>Zoi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hatzichristou</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5O8R96XMH7</RegistryNumber><NameOfSubstance UI="D000069058">Vardenafil Dihydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2006 Jul;50(1):31-3</RefSource><PMID Version="1">16517052</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2006 Jul;50(1):29-30</RefSource><PMID Version="1">16567036</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069058" MajorTopicYN="N">Vardenafil Dihydrochloride</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16564127</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2006.02.060</ArticleId><ArticleId IdType="pii">S0302-2838(06)00305-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15692117</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4628</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Stroke</Title><ISOAbbreviation>Stroke</ISOAbbreviation></Journal><ArticleTitle>Effects of high altitude exposure on cerebral hemodynamics in normal subjects.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>560</EndPage><MedlinePgn>557-60</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Acute mountain sickness (AMS) may be an early stage of high altitude cerebral edema. If so, AMS could result from an alteration of dynamic autoregulation of cerebral blood flow resulting in overperfusion of capillaries and vasogenic cerebral edema.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We measured middle cerebral artery blood flow velocity (Vmca) by transcranial Doppler and arterial blood pressure by finger plethysmography at 490 m and 20 hours after arrival at 4559 m in 35 volunteers who had been randomized to tadalafil, dexamethasone, or placebo in a study on the pharmacological prevention of high altitude pulmonary edema. A dynamic cerebral autoregulation index (ARI) was calculated from continuous recordings of Vmca and blood pressure during transiently induced hypotension.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Altitude was associated with an increase in a cerebral-sensible AMS (AMS-C) score (P&lt;0.001) and with a decrease in arterial oxygen saturation (Sao2), whereas average Vmca or ARI did not change. However, at altitude, the subjects with the lowest ARI combined with the lowest Sao2 presented with the highest AMS-C score (P&lt;0.03). In addition, a stepwise multiple linear regression analysis on arterial Pco2, Sao2, and baseline or altitude ARI identified altitude ARI as the only significant predictor of the AMS-C score (P=0.01). The AMS-C score was lower in dexamethasone-treated subjects compared with high altitude pulmonary edema-susceptible untreated subjects. Neither tadalafil nor dexamethasone had any significant effect on Vmca or ARI.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High altitude hypoxia is associated with impairment in the regulation of the cerebral circulation that might play a role in AMS pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Osta</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Physiology, Faculty of Medicine, Free University of Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moraine</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>M&#xe9;lot</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mairb&#xe4;url</LastName><ForeName>Heimo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Maggiorini</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Naeije</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stroke</MedlineTA><NlmUniqueID>0235266</NlmUniqueID><ISSNLinking>0039-2499</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000531" MajorTopicYN="Y">Altitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000532" MajorTopicYN="N">Altitude Sickness</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002536" MajorTopicYN="N">Cerebral Arteries</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009051" MajorTopicYN="N">Mountaineering</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017585" MajorTopicYN="N">Ultrasonography, Doppler, Transcranial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15692117</ArticleId><ArticleId IdType="doi">10.1161/01.STR.0000155735.85888.13</ArticleId><ArticleId IdType="pii">01.STR.0000155735.85888.13</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15359583</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0724-8741</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pharmaceutical research</Title><ISOAbbreviation>Pharm Res</ISOAbbreviation></Journal><ArticleTitle>Population dose-response model for tadalafil in the treatment of male erectile dysfunction.</ArticleTitle><Pagination><StartPage>1463</StartPage><EndPage>1470</EndPage><MedlinePgn>1463-70</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To determine the population dose-response relationship for tadalafil during on-demand (as-needed) administration for treatment of erectile dysfunction (ED).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 212 male patients with mild, moderate, or severe ED participated in a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Patients were randomized to receive placebo or 2, 5, 10, or 25 mg tadalafil, taken on demand over an 8-week period. Efficacy was assessed on the basis of questions 2 and 3 of the Sexual Encounter Profile (SEP) and questions 3 and 4 of the International Index of Erectile Function (IIEF) questionaires. These scores were modeled using logistic regression. A fifth patient response, the IIEF EF (erectile function) domain score, was modeled as a continuous variable.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The dose-response relationship for each efficacy variable was best described with an Emax model, in which maximum effect increased with ED severity at baseline. Response scores increased substantially between 10 and 25 mg tadalafil doses, and the dose-response parameter estimates suggested possibly higher responses at even higher doses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Population dose-response modeling of all five oucome measures indicated that efficacy in all ED severity groups in the studied population generally increased across the 2 to 25 mg tadalafil dose range. Estimates of maximal improvement (Emax) in the IIEF EF domain score were 7.5, 11.4, and 16.3 points for patients with mild, moderate, and severe ED, respectively. Corresponding tadalafil doses to attain half-maximal improvement (ED50 estimates) were 4.7 mg, 7.1 mg, and 10.1 mg.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Staab</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Pharmacokinetics/Pharmacodynamics and Trial Simulation, Lilly Research Center, Windlesham, Surrey, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tillmann</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Forgue</LastName><ForeName>S Thomas</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Mackie</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Allerheiligen</LastName><ForeName>Sandra R B</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Rapado</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Troc&#xf3;niz</LastName><ForeName>I&#xf1;aki F</ForeName><Initials>IF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharm Res</MedlineTA><NlmUniqueID>8406521</NlmUniqueID><ISSNLinking>0724-8741</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D015106">3',5'-Cyclic-GMP Phosphodiesterases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="D054706">Cyclic Nucleotide Phosphodiesterases, Type 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.35</RegistryNumber><NameOfSubstance UI="C517381">PDE5A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015106" MajorTopicYN="N">3',5'-Cyclic-GMP Phosphodiesterases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054706" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15359583</ArticleId><ArticleId IdType="doi">10.1023/b:pham.0000036922.03519.40</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 1999 May 14;274(20):13729-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10318772</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Feb 10;281(6):537-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10022110</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 1989;41(3):479-502</Citation><ArticleIdList><ArticleId IdType="pubmed">2541452</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Sex Behav. 1990 Aug;19(4):389-408</Citation><ArticleIdList><ArticleId IdType="pubmed">2205172</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1996 Dec;156(6):2007-11</Citation><ArticleIdList><ArticleId IdType="pubmed">8911378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Physiol Biochem Pharmacol. 1999;135:67-104</Citation><ArticleIdList><ArticleId IdType="pubmed">9932481</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2002 Feb;14 Suppl 1:S57-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11850737</ArticleId></ArticleIdList></Reference><Reference><Citation>Urol Clin North Am. 1988 Feb;15(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3278478</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Impot Res. 2001 Feb;13(1):2-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11313831</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1994 Sep;56(3):309-22</Citation><ArticleIdList><ArticleId IdType="pubmed">7924127</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacokinet Biopharm. 1993 Dec;21(6):735-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8138894</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1993 Jul 7;270(1):83-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8510302</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1996 Dec;60(6):619-35</Citation><ArticleIdList><ArticleId IdType="pubmed">8988064</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 2002 Oct;168(4 Pt 1):1332-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12352386</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1992 Jan 9;326(2):90-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1309211</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1999 Aug;54(2):346-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10443736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacokinet Biopharm. 1998 Oct;26(5):581-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10205772</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12</Citation><ArticleIdList><ArticleId IdType="pubmed">7310648</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 1997 Jun;49(6):822-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9187685</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2000 May;38(5):449-59</Citation><ArticleIdList><ArticleId IdType="pubmed">10843462</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Feb 3;281(5):421-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9952201</ArticleId></ArticleIdList></Reference><Reference><Citation>Urology. 2000 Sep 1;56(3):477-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10962319</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2001 Apr;69(4):210-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11309549</ArticleId></ArticleIdList></Reference><Reference><Citation>J Urol. 1994 Jan;151(1):54-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8254833</ArticleId></ArticleIdList></Reference><Reference><Citation>BJU Int. 1999 Jul;84(1):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10444124</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2001 Aug;95(2):324-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11506101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
